<!DOCTYPE html>
<html lang="en">
<head>
    <meta charset="UTF-8">
    <meta name="viewport" content="width=device-width, initial-scale=1.0">
    <title>Extraction extraction-result-8023 - Theorizer</title>
    <link rel="stylesheet" href="https://cdnjs.cloudflare.com/ajax/libs/font-awesome/5.15.1/css/all.min.css">
    <link rel="stylesheet" href="../style.css">
</head>
<body>
    <div class="header">
        <a href="../index.html"><i class="fas fa-flask"></i> Theorizer</a>
    </div>

    <div class="content">
        <h1>Extracted Data Details for extraction-result-8023</h1>

        <div class="section">
            <h2>Extracted Data (Header)</h2>
            <div class="info-section">
                <p><strong>Extraction ID:</strong> extraction-result-8023</p>
                <p><strong>Extraction Schema Used (ID):</strong> <a href="../schemas/extraction-schema-148.html">extraction-schema-148</a></p>
                <div class="extraction-query"><strong>Extraction Query:</strong> Extract any mentions of neuronal populations within the visual (occipital) cortex that show selective vulnerability or resistance to amyloid‑β plaques or tau tangles in dementia, including details on cell type, cortical layer, subregion, pathology type, reported mechanisms, experimental models, quantitative measures, species, disease stage, and any contrasting findings.</div>
                <p><strong>Paper ID:</strong> paper-260922364</p>
                <p><strong>Paper Title:</strong> Spatial transcriptomic patterns underlying regional vulnerability to amyloid-β and tau pathologies and their relationships to cognitive dysfunction in Alzheimer’s disease</p>
                <p><strong>Paper Abstract:</strong> One Sentence Summary: We</p>
                <p><strong>Cost:</strong> 0.015</p>
            </div>
        </div>

        <div class="section">
            <h2>Extracted Data (Details)</h2>
            <div class="extraction-instance-container" id="e8023.0">
                <h3 class="extraction-instance">Extracted Data Instance 0 (e8023.0)</h3>
                <div class="extraction-query"><strong>Extraction Query:</strong> Extract any mentions of neuronal populations within the visual (occipital) cortex that show selective vulnerability or resistance to amyloid‑β plaques or tau tangles in dementia, including details on cell type, cortical layer, subregion, pathology type, reported mechanisms, experimental models, quantitative measures, species, disease stage, and any contrasting findings.</div>
                <table>
                    <thead>
                        <tr>
                            <th style="width: 30%;">Field</th>
                            <th style="width: 70%;">Value</th>
                        </tr>
                    </thead>
                    <tbody>
                        <tr>
                            <td><strong>name_short</strong></td>
                            <td>Visual cortex (overall regional neurons)</td>
                        </tr>
                        <tr>
                            <td><strong>name_full</strong></td>
                            <td>Occipital (visual) cortex — aggregate regional neuronal population</td>
                        </tr>
                        <tr>
                            <td><strong>brief_description</strong></td>
                            <td>The paper reports that the visual (occipital) cortex shows relatively lower amyloid-β PET signal compared with many other cortical regions in MCI and AD, indicating relative resistance of the regional neuronal population to amyloid-β plaque burden at the group level; this observation is based on human PET imaging and linked to regional transcriptomic module anatomy (posterior occipitoparietal module).</td>
                        </tr>
                        <tr>
                            <td><strong>citation_title</strong></td>
                            <td>here</td>
                        </tr>
                        <tr>
                            <td><strong>mention_or_use</strong></td>
                            <td>use</td>
                        </tr>
                        <tr>
                            <td><strong>neuronal_population</strong></td>
                            <td>unspecified cortical neurons (aggregate regional population within visual/occipital cortex)</td>
                        </tr>
                        <tr>
                            <td><strong>cortical_subregion</strong></td>
                            <td>visual cortex / posterior occipitoparietal region (as part of gene co-expression module #3)</td>
                        </tr>
                        <tr>
                            <td><strong>cortical_layer</strong></td>
                            <td><span class="empty-note">null</span></td>
                        </tr>
                        <tr>
                            <td><strong>vulnerability_status</strong></td>
                            <td>resistant</td>
                        </tr>
                        <tr>
                            <td><strong>pathology_type</strong></td>
                            <td>amyloid‑β plaques</td>
                        </tr>
                        <tr>
                            <td><strong>evidence_source</strong></td>
                            <td>human in vivo PET imaging (ADNI and IMAS cohorts) correlated with Allen Human Brain Atlas regional gene expression</td>
                        </tr>
                        <tr>
                            <td><strong>experimental_method</strong></td>
                            <td>Aβ PET imaging using [18F]florbetapir (AV45) and [18F]florbetaben (FBB) with case‑control regional T-statistic maps; spatial correlation to AHBA regional transcriptome</td>
                        </tr>
                        <tr>
                            <td><strong>quantitative_measure</strong></td>
                            <td><span class="empty-note">null</span></td>
                        </tr>
                        <tr>
                            <td><strong>reported_mechanism</strong></td>
                            <td>Not directly established for visual cortex neurons; authors report regional lower Aβ PET signal and link regional patterns to spatial gene expression modules (visual cortex is part of posterior occipitoparietal module), but no cell-type or layer-specific mechanism is provided for Aβ resistance in visual cortex.</td>
                        </tr>
                        <tr>
                            <td><strong>associated_genes_proteins</strong></td>
                            <td>Genes expressed in the posterior occipitoparietal gene co-expression module (#3); no single protein marker of visual cortical neuronal resistance is specified in the paper.</td>
                        </tr>
                        <tr>
                            <td><strong>species</strong></td>
                            <td>Homo sapiens</td>
                        </tr>
                        <tr>
                            <td><strong>disease_stage</strong></td>
                            <td>MCI and Alzheimer's disease (case vs control comparisons used)</td>
                        </tr>
                        <tr>
                            <td><strong>counter_evidence</strong></td>
                            <td>None reported in this paper for visual cortex Aβ resistance; authors note overall that Aβ initially accumulates in medial frontal/parietal DMN regions (consistent with differential regional vulnerability), but do not provide contrary measures showing visual cortex vulnerability.</td>
                        </tr>
                        <tr>
                            <td><strong>reference_citation</strong></td>
                            <td>10.1101/2023.08.12.232940171</td>
                        </tr>
                    </tbody>
                </table>
            </div>
            <div class="extraction-instance-container" id="e8023.1">
                <h3 class="extraction-instance">Extracted Data Instance 1 (e8023.1)</h3>
                <div class="extraction-query"><strong>Extraction Query:</strong> Extract any mentions of neuronal populations within the visual (occipital) cortex that show selective vulnerability or resistance to amyloid‑β plaques or tau tangles in dementia, including details on cell type, cortical layer, subregion, pathology type, reported mechanisms, experimental models, quantitative measures, species, disease stage, and any contrasting findings.</div>
                <table>
                    <thead>
                        <tr>
                            <th style="width: 30%;">Field</th>
                            <th style="width: 70%;">Value</th>
                        </tr>
                    </thead>
                    <tbody>
                        <tr>
                            <td><strong>name_short</strong></td>
                            <td>Posterior occipitoparietal module (module #3)</td>
                        </tr>
                        <tr>
                            <td><strong>name_full</strong></td>
                            <td>Posterior occipitoparietal-dominant gene co-expression module (module #3) including visual cortex</td>
                        </tr>
                        <tr>
                            <td><strong>brief_description</strong></td>
                            <td>A gene co-expression module whose average regional expression is spatially localized to posterior occipitoparietal regions (including visual cortex); in the IMAS cohort this module showed a significant negative gene-to-tau association (higher module expression associated with lower regional tau PET case-control contrast), suggesting relative resistance of regions enriched for this expression profile to tau deposition in that cohort.</td>
                        </tr>
                        <tr>
                            <td><strong>citation_title</strong></td>
                            <td>here</td>
                        </tr>
                        <tr>
                            <td><strong>mention_or_use</strong></td>
                            <td>use</td>
                        </tr>
                        <tr>
                            <td><strong>neuronal_population</strong></td>
                            <td>regional neuronal populations in posterior occipitoparietal cortex (not resolved to specific neuronal subtypes)</td>
                        </tr>
                        <tr>
                            <td><strong>cortical_subregion</strong></td>
                            <td>posterior occipitoparietal cortex (includes visual cortex, parietal regions, somatosensory cortex)</td>
                        </tr>
                        <tr>
                            <td><strong>cortical_layer</strong></td>
                            <td><span class="empty-note">null</span></td>
                        </tr>
                        <tr>
                            <td><strong>vulnerability_status</strong></td>
                            <td>resistant (to tau) in IMAS cohort; mixed/limited replication across cohorts</td>
                        </tr>
                        <tr>
                            <td><strong>pathology_type</strong></td>
                            <td>tau tangles (measured by [18F]flortaucipir PET)</td>
                        </tr>
                        <tr>
                            <td><strong>evidence_source</strong></td>
                            <td>human in vivo PET imaging (ADNI and IMAS) combined with AHBA spatial transcriptomic atlas; module-to-pathology spatial correlation analysis</td>
                        </tr>
                        <tr>
                            <td><strong>experimental_method</strong></td>
                            <td>Spatial correlation of regional average module expression (from AHBA-derived gene co-expression network) with regional tau PET case-control T-statistic maps; gene co-expression network identification via Pearson correlations and Louvain community detection</td>
                        </tr>
                        <tr>
                            <td><strong>quantitative_measure</strong></td>
                            <td>Significant negative module-to-tau association reported in IMAS cohort (PFDR < 0.05 for module-level associations), but no absolute SUVR or percent differences for this module's regions are provided in the paper.</td>
                        </tr>
                        <tr>
                            <td><strong>reported_mechanism</strong></td>
                            <td>Not specified at the cellular-layer level; more broadly, gene set enrichment showed tau-related positive associations with synaptic/postsynaptic and cytosolic ribosome gene sets, but the paper does not ascribe a specific mechanistic explanation for why module #3 regions show negative association with tau in IMAS.</td>
                        </tr>
                        <tr>
                            <td><strong>associated_genes_proteins</strong></td>
                            <td>The module is an average of many genes (module #3 members); the paper does not list specific single-gene drivers of module #3 effect in the visual cortex. Global tau-related genes identified elsewhere in the study include MAPT, APOE, AGRN, PLD3, ADAMTS4, CD2AP, but their spatial relationships vary by gene and cohort.</td>
                        </tr>
                        <tr>
                            <td><strong>species</strong></td>
                            <td>Homo sapiens</td>
                        </tr>
                        <tr>
                            <td><strong>disease_stage</strong></td>
                            <td>MCI and Alzheimer's disease (module-to-pathology associations derived from case-control contrasts across the AD continuum)</td>
                        </tr>
                        <tr>
                            <td><strong>counter_evidence</strong></td>
                            <td>Module #3 negative gene-to-tau association was significant in the IMAS cohort but not consistently across both cohorts (i.e., replication was limited); the paper reports module‑level tau associations vary across modules and cohorts (modules 1 and 2 had more consistent positive/negative associations across cohorts).</td>
                        </tr>
                        <tr>
                            <td><strong>reference_citation</strong></td>
                            <td>10.1101/2023.08.12.232940171</td>
                        </tr>
                    </tbody>
                </table>
            </div>
            <div class="extraction-instance-container" id="e8023.2">
                <h3 class="extraction-instance">Extracted Data Instance 2 (e8023.2)</h3>
                <div class="extraction-query"><strong>Extraction Query:</strong> Extract any mentions of neuronal populations within the visual (occipital) cortex that show selective vulnerability or resistance to amyloid‑β plaques or tau tangles in dementia, including details on cell type, cortical layer, subregion, pathology type, reported mechanisms, experimental models, quantitative measures, species, disease stage, and any contrasting findings.</div>
                <table>
                    <thead>
                        <tr>
                            <th style="width: 30%;">Field</th>
                            <th style="width: 70%;">Value</th>
                        </tr>
                    </thead>
                    <tbody>
                        <tr>
                            <td><strong>name_short</strong></td>
                            <td>Visual cortex – transcriptomic pathway signature (implicit neuronal vulnerability)</td>
                        </tr>
                        <tr>
                            <td><strong>name_full</strong></td>
                            <td>Visual/occipital regional transcriptomic signature implicating synaptic and postsynaptic gene sets in tau vulnerability</td>
                        </tr>
                        <tr>
                            <td><strong>brief_description</strong></td>
                            <td>Genome‑wide spatial correlations and GSEA identified that regional tau vulnerability across cortex is positively associated with high expression of gene sets involved in cytosolic ribosome, synaptic and postsynaptic functions, implying that neurons with high synaptic gene expression (where present) are more associated with tau deposition patterns; this is a region-level transcriptomic inference rather than a cell-type resolved observation within visual cortex.</td>
                        </tr>
                        <tr>
                            <td><strong>citation_title</strong></td>
                            <td>here</td>
                        </tr>
                        <tr>
                            <td><strong>mention_or_use</strong></td>
                            <td>use</td>
                        </tr>
                        <tr>
                            <td><strong>neuronal_population</strong></td>
                            <td>neuronal populations characterized by high synaptic/postsynaptic gene expression (not cell-type or layer resolved; may include excitatory cortical neurons)</td>
                        </tr>
                        <tr>
                            <td><strong>cortical_subregion</strong></td>
                            <td>regions showing tau vulnerability (medial temporal and inferior/middle temporal cortices primarily); application to visual cortex is inferential (visual cortex showed lower Aβ and module-level negative tau association in one cohort)</td>
                        </tr>
                        <tr>
                            <td><strong>cortical_layer</strong></td>
                            <td><span class="empty-note">null</span></td>
                        </tr>
                        <tr>
                            <td><strong>vulnerability_status</strong></td>
                            <td>vulnerable (neurons with high synaptic/postsynaptic gene expression show positive association with tau vulnerability across cortex), though visual cortex specifically showed lower Aβ and module #3 negative tau association in one cohort</td>
                        </tr>
                        <tr>
                            <td><strong>pathology_type</strong></td>
                            <td>tau tangles (primary association) and inferred relationships across regions</td>
                        </tr>
                        <tr>
                            <td><strong>evidence_source</strong></td>
                            <td>human in vivo PET imaging correlated with AHBA transcriptome and gene set enrichment analysis (GSEA)</td>
                        </tr>
                        <tr>
                            <td><strong>experimental_method</strong></td>
                            <td>Genome-wide spatial correlation (15,745 genes) between AHBA expression and PET-derived regional vulnerability maps, followed by GSEA (GSEAPreranked) to identify enriched GO gene sets</td>
                        </tr>
                        <tr>
                            <td><strong>quantitative_measure</strong></td>
                            <td>GSEA produced normalized enrichment scores and FDR‑corrected significance (11 positively enriched gene sets related to tau reported; exact NES values not reproduced in main text), but no cell-level quantitative measures in visual cortex are provided.</td>
                        </tr>
                        <tr>
                            <td><strong>reported_mechanism</strong></td>
                            <td>Authors propose that high regional expression of synaptic/postsynaptic and ribosomal gene sets may underlie regional vulnerability to tau deposition (i.e., neurons with heavy synaptic machinery may be predisposed to tau accumulation/spread), but this is correlative and not proven causally.</td>
                        </tr>
                        <tr>
                            <td><strong>associated_genes_proteins</strong></td>
                            <td>Enriched GO gene sets (cytosolic ribosome, synaptic and postsynaptic functions); individual tau-related genes identified elsewhere include MAPT, APOE, AGRN, PLD3, CD2AP, ADAMTS4 but their spatial relations differ by gene.</td>
                        </tr>
                        <tr>
                            <td><strong>species</strong></td>
                            <td>Homo sapiens</td>
                        </tr>
                        <tr>
                            <td><strong>disease_stage</strong></td>
                            <td>Across AD continuum (CU, MCI, AD); tau associations derived from case-control contrasts</td>
                        </tr>
                        <tr>
                            <td><strong>counter_evidence</strong></td>
                            <td>Visual cortex and some posterior regions showed lower PET tau/Aβ signals than other regions in group contrasts; thus, while synaptic gene expression correlates with tau vulnerability regionally, visual cortex appeared relatively spared in Aβ and showed module-specific negative tau association in one cohort, indicating heterogeneous regional relationships.</td>
                        </tr>
                        <tr>
                            <td><strong>reference_citation</strong></td>
                            <td>10.1101/2023.08.12.232940171</td>
                        </tr>
                    </tbody>
                </table>
            </div>
        </div>

        <div class="section">
            <h2>Potentially Relevant New Papers (mentioned by this paper)</h2>
            <ol>
                <li>Neurogenetic contributions to amyloid beta and tau spreading in the human cortex <em>(Rating: 2)</em></li>
                <li>Molecular properties underlying regional vulnerability to Alzheimer's disease pathology <em>(Rating: 2)</em></li>
                <li>Transcriptional Signatures of Tau and Amyloid Neuropathology <em>(Rating: 2)</em></li>
                <li>Spatial Transcriptomics and In Situ Sequencing to Study Alzheimer's Disease <em>(Rating: 2)</em></li>
                <li>Single-cell transcriptomic analysis of Alzheimer's disease <em>(Rating: 2)</em></li>
                <li>Four distinct trajectories of tau deposition identified in Alzheimer's disease <em>(Rating: 1)</em></li>
            </ol>
        </div>

        <div class="section">
            <h2>Extracted Data (Debug)</h2>
            <pre><code>{
    "id": "extraction-result-8023",
    "paper_id": "paper-260922364",
    "extraction_schema_id": "extraction-schema-148",
    "extracted_data": [
        {
            "name_short": "Visual cortex (overall regional neurons)",
            "name_full": "Occipital (visual) cortex — aggregate regional neuronal population",
            "brief_description": "The paper reports that the visual (occipital) cortex shows relatively lower amyloid-β PET signal compared with many other cortical regions in MCI and AD, indicating relative resistance of the regional neuronal population to amyloid-β plaque burden at the group level; this observation is based on human PET imaging and linked to regional transcriptomic module anatomy (posterior occipitoparietal module).",
            "citation_title": "here",
            "mention_or_use": "use",
            "neuronal_population": "unspecified cortical neurons (aggregate regional population within visual/occipital cortex)",
            "cortical_subregion": "visual cortex / posterior occipitoparietal region (as part of gene co-expression module #3)",
            "cortical_layer": null,
            "vulnerability_status": "resistant",
            "pathology_type": "amyloid‑β plaques",
            "evidence_source": "human in vivo PET imaging (ADNI and IMAS cohorts) correlated with Allen Human Brain Atlas regional gene expression",
            "experimental_method": "Aβ PET imaging using [18F]florbetapir (AV45) and [18F]florbetaben (FBB) with case‑control regional T-statistic maps; spatial correlation to AHBA regional transcriptome",
            "quantitative_measure": null,
            "reported_mechanism": "Not directly established for visual cortex neurons; authors report regional lower Aβ PET signal and link regional patterns to spatial gene expression modules (visual cortex is part of posterior occipitoparietal module), but no cell-type or layer-specific mechanism is provided for Aβ resistance in visual cortex.",
            "associated_genes_proteins": "Genes expressed in the posterior occipitoparietal gene co-expression module (#3); no single protein marker of visual cortical neuronal resistance is specified in the paper.",
            "species": "Homo sapiens",
            "disease_stage": "MCI and Alzheimer's disease (case vs control comparisons used)",
            "counter_evidence": "None reported in this paper for visual cortex Aβ resistance; authors note overall that Aβ initially accumulates in medial frontal/parietal DMN regions (consistent with differential regional vulnerability), but do not provide contrary measures showing visual cortex vulnerability.",
            "reference_citation": "10.1101/2023.08.12.232940171",
            "uuid": "e8023.0"
        },
        {
            "name_short": "Posterior occipitoparietal module (module #3)",
            "name_full": "Posterior occipitoparietal-dominant gene co-expression module (module #3) including visual cortex",
            "brief_description": "A gene co-expression module whose average regional expression is spatially localized to posterior occipitoparietal regions (including visual cortex); in the IMAS cohort this module showed a significant negative gene-to-tau association (higher module expression associated with lower regional tau PET case-control contrast), suggesting relative resistance of regions enriched for this expression profile to tau deposition in that cohort.",
            "citation_title": "here",
            "mention_or_use": "use",
            "neuronal_population": "regional neuronal populations in posterior occipitoparietal cortex (not resolved to specific neuronal subtypes)",
            "cortical_subregion": "posterior occipitoparietal cortex (includes visual cortex, parietal regions, somatosensory cortex)",
            "cortical_layer": null,
            "vulnerability_status": "resistant (to tau) in IMAS cohort; mixed/limited replication across cohorts",
            "pathology_type": "tau tangles (measured by [18F]flortaucipir PET)",
            "evidence_source": "human in vivo PET imaging (ADNI and IMAS) combined with AHBA spatial transcriptomic atlas; module-to-pathology spatial correlation analysis",
            "experimental_method": "Spatial correlation of regional average module expression (from AHBA-derived gene co-expression network) with regional tau PET case-control T-statistic maps; gene co-expression network identification via Pearson correlations and Louvain community detection",
            "quantitative_measure": "Significant negative module-to-tau association reported in IMAS cohort (PFDR &lt; 0.05 for module-level associations), but no absolute SUVR or percent differences for this module's regions are provided in the paper.",
            "reported_mechanism": "Not specified at the cellular-layer level; more broadly, gene set enrichment showed tau-related positive associations with synaptic/postsynaptic and cytosolic ribosome gene sets, but the paper does not ascribe a specific mechanistic explanation for why module #3 regions show negative association with tau in IMAS.",
            "associated_genes_proteins": "The module is an average of many genes (module #3 members); the paper does not list specific single-gene drivers of module #3 effect in the visual cortex. Global tau-related genes identified elsewhere in the study include MAPT, APOE, AGRN, PLD3, ADAMTS4, CD2AP, but their spatial relationships vary by gene and cohort.",
            "species": "Homo sapiens",
            "disease_stage": "MCI and Alzheimer's disease (module-to-pathology associations derived from case-control contrasts across the AD continuum)",
            "counter_evidence": "Module #3 negative gene-to-tau association was significant in the IMAS cohort but not consistently across both cohorts (i.e., replication was limited); the paper reports module‑level tau associations vary across modules and cohorts (modules 1 and 2 had more consistent positive/negative associations across cohorts).",
            "reference_citation": "10.1101/2023.08.12.232940171",
            "uuid": "e8023.1"
        },
        {
            "name_short": "Visual cortex – transcriptomic pathway signature (implicit neuronal vulnerability)",
            "name_full": "Visual/occipital regional transcriptomic signature implicating synaptic and postsynaptic gene sets in tau vulnerability",
            "brief_description": "Genome‑wide spatial correlations and GSEA identified that regional tau vulnerability across cortex is positively associated with high expression of gene sets involved in cytosolic ribosome, synaptic and postsynaptic functions, implying that neurons with high synaptic gene expression (where present) are more associated with tau deposition patterns; this is a region-level transcriptomic inference rather than a cell-type resolved observation within visual cortex.",
            "citation_title": "here",
            "mention_or_use": "use",
            "neuronal_population": "neuronal populations characterized by high synaptic/postsynaptic gene expression (not cell-type or layer resolved; may include excitatory cortical neurons)",
            "cortical_subregion": "regions showing tau vulnerability (medial temporal and inferior/middle temporal cortices primarily); application to visual cortex is inferential (visual cortex showed lower Aβ and module-level negative tau association in one cohort)",
            "cortical_layer": null,
            "vulnerability_status": "vulnerable (neurons with high synaptic/postsynaptic gene expression show positive association with tau vulnerability across cortex), though visual cortex specifically showed lower Aβ and module #3 negative tau association in one cohort",
            "pathology_type": "tau tangles (primary association) and inferred relationships across regions",
            "evidence_source": "human in vivo PET imaging correlated with AHBA transcriptome and gene set enrichment analysis (GSEA)",
            "experimental_method": "Genome-wide spatial correlation (15,745 genes) between AHBA expression and PET-derived regional vulnerability maps, followed by GSEA (GSEAPreranked) to identify enriched GO gene sets",
            "quantitative_measure": "GSEA produced normalized enrichment scores and FDR‑corrected significance (11 positively enriched gene sets related to tau reported; exact NES values not reproduced in main text), but no cell-level quantitative measures in visual cortex are provided.",
            "reported_mechanism": "Authors propose that high regional expression of synaptic/postsynaptic and ribosomal gene sets may underlie regional vulnerability to tau deposition (i.e., neurons with heavy synaptic machinery may be predisposed to tau accumulation/spread), but this is correlative and not proven causally.",
            "associated_genes_proteins": "Enriched GO gene sets (cytosolic ribosome, synaptic and postsynaptic functions); individual tau-related genes identified elsewhere include MAPT, APOE, AGRN, PLD3, CD2AP, ADAMTS4 but their spatial relations differ by gene.",
            "species": "Homo sapiens",
            "disease_stage": "Across AD continuum (CU, MCI, AD); tau associations derived from case-control contrasts",
            "counter_evidence": "Visual cortex and some posterior regions showed lower PET tau/Aβ signals than other regions in group contrasts; thus, while synaptic gene expression correlates with tau vulnerability regionally, visual cortex appeared relatively spared in Aβ and showed module-specific negative tau association in one cohort, indicating heterogeneous regional relationships.",
            "reference_citation": "10.1101/2023.08.12.232940171",
            "uuid": "e8023.2"
        }
    ],
    "potentially_relevant_new_papers": [
        {
            "paper_title": "Neurogenetic contributions to amyloid beta and tau spreading in the human cortex",
            "rating": 2,
            "sanitized_title": "neurogenetic_contributions_to_amyloid_beta_and_tau_spreading_in_the_human_cortex"
        },
        {
            "paper_title": "Molecular properties underlying regional vulnerability to Alzheimer's disease pathology",
            "rating": 2,
            "sanitized_title": "molecular_properties_underlying_regional_vulnerability_to_alzheimers_disease_pathology"
        },
        {
            "paper_title": "Transcriptional Signatures of Tau and Amyloid Neuropathology",
            "rating": 2,
            "sanitized_title": "transcriptional_signatures_of_tau_and_amyloid_neuropathology"
        },
        {
            "paper_title": "Spatial Transcriptomics and In Situ Sequencing to Study Alzheimer's Disease",
            "rating": 2,
            "sanitized_title": "spatial_transcriptomics_and_in_situ_sequencing_to_study_alzheimers_disease"
        },
        {
            "paper_title": "Single-cell transcriptomic analysis of Alzheimer's disease",
            "rating": 2,
            "sanitized_title": "singlecell_transcriptomic_analysis_of_alzheimers_disease"
        },
        {
            "paper_title": "Four distinct trajectories of tau deposition identified in Alzheimer's disease",
            "rating": 1,
            "sanitized_title": "four_distinct_trajectories_of_tau_deposition_identified_in_alzheimers_disease"
        }
    ],
    "cost": 0.015481749999999999,
    "model_str": "gpt-5-mini"
}</code></pre>
        </div>
        <div class="section">
            <h2>Paper</h2>
            <div class="paper-content"><p>Spatial transcriptomic patterns underlying regional vulnerability to amyloid-β and tau pathologies and their relationships to cognitive dysfunction in Alzheimer's disease</p>
<p>Meichen Yu 
Indiana Alzheimer's Disease Research Center
Indiana University School of Medicine
IndianapolisINU.S.A</p>
<p>Center for Neuroimaging
Department of Radiology and Imaging Sciences
Indiana University School of Medicine
IndianapolisINU.S.A</p>
<p>Stark Neurosciences Research Institute
Indiana University School of Medicine
IndianapolisINUSA</p>
<p>Indiana University Network Science Institute
BloomingtonINUSA</p>
<p>Shannon L Risacher 
Indiana Alzheimer's Disease Research Center
Indiana University School of Medicine
IndianapolisINU.S.A</p>
<p>Center for Neuroimaging
Department of Radiology and Imaging Sciences
Indiana University School of Medicine
IndianapolisINU.S.A</p>
<p>Stark Neurosciences Research Institute
Indiana University School of Medicine
IndianapolisINUSA</p>
<p>Kwangsik T Nho 
Indiana Alzheimer's Disease Research Center
Indiana University School of Medicine
IndianapolisINU.S.A</p>
<p>Center for Neuroimaging
Department of Radiology and Imaging Sciences
Indiana University School of Medicine
IndianapolisINU.S.A</p>
<p>Stark Neurosciences Research Institute
Indiana University School of Medicine
IndianapolisINUSA</p>
<p>Indiana University Network Science Institute
BloomingtonINUSA</p>
<p>Qiuting Wen 
Indiana Alzheimer's Disease Research Center
Indiana University School of Medicine
IndianapolisINU.S.A</p>
<p>Center for Neuroimaging
Department of Radiology and Imaging Sciences
Indiana University School of Medicine
IndianapolisINU.S.A</p>
<p>Adrian L Oblak 
Center for Neuroimaging
Department of Radiology and Imaging Sciences
Indiana University School of Medicine
IndianapolisINU.S.A</p>
<p>Stark Neurosciences Research Institute
Indiana University School of Medicine
IndianapolisINUSA</p>
<p>Frederick W Unverzagt 
Indiana Alzheimer's Disease Research Center
Indiana University School of Medicine
IndianapolisINU.S.A</p>
<p>Department of Psychiatry
Indiana University School of Medicine
IndianapolisINU.S.A</p>
<p>Liana G Apostolova 
Indiana Alzheimer's Disease Research Center
Indiana University School of Medicine
IndianapolisINU.S.A</p>
<p>Center for Neuroimaging
Department of Radiology and Imaging Sciences
Indiana University School of Medicine
IndianapolisINU.S.A</p>
<p>Stark Neurosciences Research Institute
Indiana University School of Medicine
IndianapolisINUSA</p>
<p>Department of Neurology
Indiana University School of Medicine
IndianapolisINU.S.A</p>
<p>Department of Medical and Molecular Genetics
Indiana University School of Medicine
IndianapolisINU.S.A</p>
<p>Martin R Farlow 
Indiana Alzheimer's Disease Research Center
Indiana University School of Medicine
IndianapolisINU.S.A</p>
<p>Stark Neurosciences Research Institute
Indiana University School of Medicine
IndianapolisINUSA</p>
<p>Department of Neurology
Indiana University School of Medicine
IndianapolisINU.S.A</p>
<p>Jared R Brosch 
Indiana Alzheimer's Disease Research Center
Indiana University School of Medicine
IndianapolisINU.S.A</p>
<p>Department of Neurology
Indiana University School of Medicine
IndianapolisINU.S.A</p>
<p>David G Clark 
Indiana Alzheimer's Disease Research Center
Indiana University School of Medicine
IndianapolisINU.S.A</p>
<p>Department of Neurology
Indiana University School of Medicine
IndianapolisINU.S.A</p>
<p>Sophia Wang 
Indiana Alzheimer's Disease Research Center
Indiana University School of Medicine
IndianapolisINU.S.A</p>
<p>Department of Psychiatry
Indiana University School of Medicine
IndianapolisINU.S.A</p>
<p>Rachael Deardorff 
Indiana Alzheimer's Disease Research Center
Indiana University School of Medicine
IndianapolisINU.S.A</p>
<p>Center for Neuroimaging
Department of Radiology and Imaging Sciences
Indiana University School of Medicine
IndianapolisINU.S.A</p>
<p>Yu-Chien Wu 
Indiana Alzheimer's Disease Research Center
Indiana University School of Medicine
IndianapolisINU.S.A</p>
<p>Center for Neuroimaging
Department of Radiology and Imaging Sciences
Indiana University School of Medicine
IndianapolisINU.S.A</p>
<p>Stark Neurosciences Research Institute
Indiana University School of Medicine
IndianapolisINUSA</p>
<p>Sujuan Gao 
Indiana Alzheimer's Disease Research Center
Indiana University School of Medicine
IndianapolisINU.S.A</p>
<p>Department of Biostatistics and Health Data Science
Indiana University School of Medicine
IndianapolisIndianaUSA</p>
<p>Olaf Sporns 
Indiana Alzheimer's Disease Research Center
Indiana University School of Medicine
IndianapolisINU.S.A</p>
<p>Center for Neuroimaging
Department of Radiology and Imaging Sciences
Indiana University School of Medicine
IndianapolisINU.S.A</p>
<p>Indiana University Network Science Institute
BloomingtonINUSA</p>
<p>Department of Psychological and Brain Sciences
Indiana University
BloomingtonINUSA</p>
<p>Andrew J Saykin 
Indiana Alzheimer's Disease Research Center
Indiana University School of Medicine
IndianapolisINU.S.A</p>
<p>Center for Neuroimaging
Department of Radiology and Imaging Sciences
Indiana University School of Medicine
IndianapolisINU.S.A</p>
<p>Stark Neurosciences Research Institute
Indiana University School of Medicine
IndianapolisINUSA</p>
<p>Indiana University Network Science Institute
BloomingtonINUSA</p>
<p>Spatial transcriptomic patterns underlying regional vulnerability to amyloid-β and tau pathologies and their relationships to cognitive dysfunction in Alzheimer's disease
10.1101/2023.08.12.232940171 for the Alzheimer's Disease Neuroimaging Initiative (ADNI) Affiliations: * Correspondence to: meiyu@iu.edu (Meichen Yu, Ph.D.) and asaykin@iupui.edu (Andrew J. Saykin, Psy.D.) All rights reserved. No reuse allowed without permission. (which was not certified by peer review) is the author/funder, who has granted medRxiv a license to display the preprint in perpetuity. The copyright holder for this preprint this version posted August 16, 2023. ; All rights reserved. No reuse allowed without permission. (which was not certified by peer review) is the author/funder, who has granted medRxiv a license to display the preprint in perpetuity. The copyright holder for this preprint this version posted August 16, 2023. ;Alzheimer's diseaseamyloid-βcognitive dysfunctiongene expressionpathologytau
medRxiv preprint NOTE: This preprint reports new research that has not been certified by peer review and should not be used to guide clinical practice.One Sentence Summary: We identified replicable cognition-related associations between regional gene expression profiles and selectively regional vulnerability to amyloid-β and tau pathologies in AD.Abstract: Amyloid-β (Aβ) and tau proteins accumulate within distinct neuronal systems in Alzheimer's disease (AD). Although it is not clear why certain brain regions are more vulnerable to Aβ and tau pathologies than others, gene expression may play a role. We studied the association between brain-wide gene expression profiles and regional vulnerability to Aβ (gene-to-Aβ associations) and tau (gene-to-tau associations) pathologies leveraging two large independent cohorts (n = 715) of participants along the AD continuum. We identified several AD susceptibility genes and gene modules in a gene co-expression network with expression profiles related to regional vulnerability to Aβ and tau pathologies in AD. In particular, we found that the positive APOE-to-tau association was only seen in the AD cohort, whereas patients with AD and frontotemporal dementia shared similar positive MAPT-to-tau association. Some AD candidate genes showed sex-dependent negative gene-to-Aβ and gene-to-tau associations. In addition, we identified distinct biochemical pathways associated with the gene-to-Aβ and the gene-to-tau associations. Finally, we proposed a novel analytic framework, linking the identified gene-topathology associations to cognitive dysfunction in AD at the individual level, suggesting potential clinical implication of the gene-to-pathology associations. Taken together, our study identified distinct gene expression profiles and biochemical pathways that may explain the discordance between regional Aβ and tau pathologies, and filled the gap between gene-to-pathology associations and cognitive dysfunction in individual AD patients that may ultimately help identify novel personalized pathogenetic biomarkers and therapeutic targets.</p>
<p>INTRODUCTION</p>
<p>Abnormal accumulations of amyloid-β (Aβ) and tau proteins in the brain are two principal neuropathological hallmarks of Alzheimer's disease (AD). Aβ and tau pathologies affect distinct neuronal systems, leading to neurodegeneration and cognitive decline in AD 1-3 . Using positron emission tomography (PET), many studies have reported that Aβ initially accumulates in the medial frontal cortex and medial parietal cortex 4 , both parts of the default mode network 5,6 . In contrast, tau is initially deposited in the medial temporal lobe memory system, spreading from the transentorhinal cortex to the hippocampus and parahippocampal cortex, and finally to other brain regions [7][8][9][10] . However, why distinct brain regions are more selectively vulnerable to Aβ and tau pathologies than others remain to be elucidated.</p>
<p>The recent development of brain-wide gene expression atlas, e.g., the Allen Human Brain Atlas (AHBA 11,12 ), has made it possible to connect spatial variations in gene expression profiles to the regional vulnerability to A and tau pathologies (gene-to-pathology associations) in AD 13,14 . For instance, three recent studies [15][16][17] have identified genes whose expression profiles are related to the spatial accumulation patterns of A and tau pathologies. Additionally, in these studies, A and tau-related biochemical pathways have also been reported. However, results from these studies are not always consistent, possibly due to the use of different approaches for processing the gene expression data and the use of PET imaging data with small sample size (n &lt; 100). Recent large-scale GWAS studies [18][19][20] have discovered many novel AD risk loci providing clues to molecular mechanisms, yet the potential of these risk loci to inform gene-to-pathology associations has not yet been studied. Moreover, A pathology is specific to AD, whereas tau pathology is shared in different types of dementia, for example, frontotemporal lobar degeneration (FTLD). It is not clear if the regional vulnerability to tau pathology and its relation to regional gene expression profiles were specific to AD or shared with FTLD. Finally, until now, the gene-to-pathology associations remain uncertain at the individual level and have not been related to cognitive dysfunction in AD patients, hindering their translation to clinical utility.</p>
<p>To fill these gaps, we tested the hypotheses that brain-wide gene expression profiles are associated with selective regional vulnerability to Aβ and tau pathologies, and that these spatial gene-to-pathology associations are related to cognitive dysfunction in AD. We used two large independent datasets, namely the Alzheimer's Disease Neuroimaging Initiative (ADNI; n = 605) and Indiana Memory and Aging Study (IMAS; n = 110) cohorts. Specifically, we used the ADNI cohort as a discovery dataset, and then used the IMAS dataset to replicate the ADNI findings. Regional gene expression profiles for 15,745 protein-coding genes were derived from brain-wide microarray-based transcriptome data from the AHBA. In this report, we conducted one hypothesis-driven analysis using a priori selected AD susceptibility genes selected from recent large-scale GWAS studies [18][19][20] and two datadriven analyses using all 15,745 genes. A schematic overview of the applied methods is provided in Fig. 1. First, in the hypothesis-driven analysis (Fig. 1A), we studied how gene expression profiles of individual AD susceptibility genes are related to regional vulnerability to Aβ (gene-to-Aβ associations) and tau (gene-to-tau associations) pathologies. We tested if the gene-to-tau associations are specific to AD or shared with FTLD by re-conducting the gene-to-tau association analysis in 11 patients with FTLD. Spatial permutation testing and gene specificity testing were performed to verify the robustness of the identified gene-to-pathology association. In a subsequent data-driven analysis (Fig. 1B), we computed spatial gene-to-amyloid-β and gene-to-tau associations for average gene expression profiles of gene modules identified from a gene co-expression network (15,745 × 15,745). Then, in another data-driven analysis (Fig. 1C), we identified biochemical pathways that may underlie the regional vulnerability to A and tau pathologies using gene set enrichment analysis (GSEA 21 ) of the full genome-wide expression profiles. Finally, we developed a novel analytic framework for estimating how cognitive impairments in AD are related to the identified gene-to-Aβ and gene-to-tau associations at the levels of individual genes and gene co-expression modules (Fig. 1D).</p>
<p>RESULTS</p>
<p>Demographics</p>
<p>Participant characteristics and cognitive scores are presented in Table 1. The ADNI sample includes 336 cognitively unimpaired (CU) individuals, 200 patients with mild cognitive impairment (MCI), and 69 patients with AD dementia. The IMAS cohort includes 38 CU, 30 MCI, and 11 AD individuals, as well as 31 individuals with subjective cognitive decline (SCD). For the ADNI cohort, age and sex showed significant group differences (P &lt; .0001); for the IMAS cohort, they did not differ across the four groups. Cognitive function of participants was assessed by both the Montreal Cognitive Assessment (MoCA) and Mini-Mental State Exam (MMSE) for the ADNI cohort and the MoCA for the IMAS cohort. The mean MoCA and MMSE scores were significantly (P &lt; .0001) lower in patients (MCI and AD) compared to the psychometrically unimpaired groups (CU and/or SCD) in both cohorts.</p>
<p>Regional vulnerability of A and tau pathologies in AD</p>
<p>In both cohorts, Aβ pathology was measured using [ 18 F]florbetapir (AV45) and [ 18 F]florbetaben (FBB) PET; tau pathology was measured using [ 18 F]flortaucipir (AV-1451) PET. We estimated the regional vulnerability to Aβ and tau pathologies by contrasting amyloid-β and tau PET imaging data between cognitively normal participants (CU in the ADNI cohort; CU and SCD in the IMAS cohort) and cognitively impaired patients (MCI and AD in two cohorts). In general, the ADNI and IMAS cohorts shared similar regional vulnerability to Aβ and tau pathologies: for Aβ, ADNI AV45 vs. ADNI FBB (Pearson's rho = 0.84, P &lt; .0001), ADNI AV45 vs. IMAS (Pearson's rho = 0.65, P &lt; .0001), ADNI FBB vs. IMAS (Pearson's rho = 0.80, P &lt; .0001); for tau, ADNI vs. IMAS (Pearson's rho = 0.88, P &lt; .0001). Specifically, in both cohorts, AD and MCI patients showed higher amyloid-β loads than CU and/or SCD, particularly in the medial parietal cortex, temporal lobe, medial and inferior prefrontal cortices, and superior and middle frontal cortices ( Fig. 2A). The medial temporal lobe and visual cortex showed relatively lower Aβ levels than other brain regions in MCI and AD. In both cohorts, AD and MCI patients also showed higher tau levels than CU and/or SCD, mainly in the medial temporal lobe, medial and inferior parietal cortices, and inferior and middle temporal cortices (Fig. 3A). The frontal lobe and sensorimotor cortex showed relatively lower tau levels than other brain regions in MCI and AD. Females showed overall higher vulnerability to Aβ (Fig. S2A) and tau (Fig. S3A) pathologies across the cortex than males, although the spatial patterns of vulnerability were generally consistent in both sexes.</p>
<p>Genetic associations of A and tau pathologies</p>
<p>In a hypothesis-driven candidate gene analysis, we computed spatial associations between gene expression profiles of 45 AD susceptibility genes and regional vulnerability to deposition of Aβ (gene-to-Aβ associations) and tau (gene-to-tau associations) pathologies (case-control T-statistic maps). In both cohorts, we identified consistent significant gene-to-Aβ and gene-to-tau associations after multiple testing adjustment for multiple genes (PFDR &lt; 0.05; (Fig. 2B; Fig. 3B)). Specifically, CNTNAP2 and TMEM106B showed the strongest positive geneto-Aβ associations, whereas INPP5D, WWOX, and HLA-DRB1 showed the strongest negative associations in AD. In contrast, APOE, MAPT, AGRN, and PLD3 showed the strongest positive gene-to-tau associations, whereas ADAMTS4 and CD2AP showed the strongest negative associations.</p>
<p>Although Aβ pathology is specific to AD, other types of dementia can feature tauopathy, including some forms of frontotemporal lobar degeneration (FTLD). Therefore, we next tested if the gene-to-tau associations were specific to an AD population or were observed in patients with FTLD. We examined the pathological specificity of the identified gene-to-tau associations in 11 patients with FTLD from the IADRC cohort and found that the positive APOE-to-tau association and the negative CD2AP-to-tau association were only seen in the AD cohort, whereas AD and FTLD shared similar positive (e.g., MAPT, AGRN, and PLD3) and negative (e.g., ADAMTS4) gene-to-tau associations in the same genes (Fig. S1).</p>
<p>The identified positive gene-to-Aβ and gene-to-tau associations were generally consistent in males (Fig. S2B) and females (Fig. S3B). Some genes showed sex-dependent negative gene-to-Aβ and gene-to-tau associations. For instance, the HLA-DRB1-and HLA-DRB5-to-Aβ associations were more pronounced in males than in females, All rights reserved. No reuse allowed without permission.</p>
<p>(which was not certified by peer review) is the author/funder, who has granted medRxiv a license to display the preprint in perpetuity.</p>
<p>The copyright holder for this preprint this version posted August 16, 2023. ; https://doi.org/10.1101/2023.08.12.23294017 doi: medRxiv preprint whereas the WWOX-to-Aβ association was only found in females. Similarly, the CD2AP-to-tau association was specific to females. The identified gene-to-Aβ and gene-to-tau associations were corrected for the effects of spatial autocorrelation and gene specificity (see Supplement Table S1). The gene-to-Aβ associations showed higher gene specificity than the gene-to-tau associations, which is consistent with our hypothesis and the results of pathological specificity analysis described above.</p>
<p>Going beyond candidate gene analysis using preselected individual genes to a data-driven analysis, we constructed a gene co-expression network by computing the Pearson correlations of gene expression profiles between all pairs of the 15,745 protein-coding genes. Next, we applied modularity maximization using the Louvain community detection algorithm 22 and a consensus clustering algorithm 23 to the 15,745 × 15,745 gene coexpression network. We identified four gene modules with distinct spatial distributions of gene expression levels ( Fig. 4A): 1) a frontotemporal-dominant module (#1) involving medial and lateral frontotemporal regions; 2) a cingulo-sensory-dominant module (#2) involving the middle and posterior cingulate cortices; 3) a posterior occipitoparietal-dominant module (#3) involving the visual cortex, parietal regions, and somatosensory cortex; 4) a medial frontoparietal-dominant module (#4) involving the anterior and isthmus cingulate cortices, medial prefrontal cortex, and lateral frontal regions. In both cohorts, module 4 showed consistent negative associations between the average gene expression profile and the regional vulnerability to Aβ deposition (Fig. 4B). In the IMAS cohort, module 2 also showed significant negative gene-to-Aβ associations. In both cohorts, module 1 and 2 showed consistent positive and negative gene-to-tau associations, respectively. In the IMAS cohort, module 3 also showed a significant negative gene-to-tau association.</p>
<p>Biochemical pathways related to gene-to-pathology associations</p>
<p>In a secondary data-driven analysis, we computed gene-to-Aβ and gene-to-tau associations for all the 15,745 genes. We then used explorative GSEA to identify potential biochemical pathways of gene sets (genes annotated by the same gene ontology (GO) term including biological processes and cellular component functions) related to the gene-to-pathology associations. We identified 4 negatively enriched gene sets (e.g., peptide antigen processing and transmembrane protein complex) associated with the gene-to-Aβ associations and 11 positively enriched gene sets (e.g., cytosolic ribosome, synaptic and postsynaptic functions, and axoneme assembly) related to the gene-to-tau associations that were consistently shown in both cohorts. Fig. 5 and Fig. 6 show representative gene enrichment plots for negatively and positively enriched GO gene sets with highest normalized enrichment scores for the gene-to-Aβ and the gene-to-tau associations, respectively. A detailed list of negatively and positively enriched gene sets identified by the GSEA is provided in Supplement Table S2.</p>
<p>Clinical implication of gene-to-pathology associations</p>
<p>We developed a novel analytic framework to study how the identified gene-to-pathology associations are related to cognitive decline in AD. Specifically, we first computed individual-level gene-to-pathology covariance values (named as pathogenetic scores [PGSs]) by estimating the covariance between regional gene expression profiles for each AD candidate gene (or gene module) and regional AD pathology (e.g., Aβ or tau deposition) values across all the individuals. Of note, this analysis was restricted to those AD candidate genes and gene modules that showed significant spatial correlations with the regional vulnerability to Aβ or tau pathologies (gene-to-Aβ and gene-to-tau associations) described above. Then, for those genes (or gene modules) showing significantly different PGCSs between patients (MCI and AD) and controls (CU and/or SCD) ( FDR &lt; 0.05), we estimated Pearson's correlations between individual-level PGSs and MoCA performance. The PGSs and their correlations to the MOCA values were calculated for Aβ (e.g., the ADNI AV45 and FBB data and IMAS Aβ data) and for tau (e.g., ADNI and IMAS tau data) data included in this study, respectively.</p>
<p>For both cohorts, the PGSs showed consistent group differences (patients vs. controls) for Aβ-related (Fig. 7) and tau-related ( Fig. 8) individual genes and gene modules (Fig. 4C, D). For Aβ-related genes (i.e., CNTNAP2 and HLA-DRB1) and gene module (e.g., module 4), the PGSs showed comparable ranges of distributions between patients and controls, whereas for tau-related genes (i.e., MAPT and APOE) and gene modules (e.g., modules 2 and 4), the PGSs showed wider distributions in patients relative to controls. For both Aβ-related and tau-related genes and gene modules, the PGSs with significantly higher values in patients than in controls were negatively associated with MoCA total score in patients (i.e., for Aβ-related genes, see CNTNAP2 in Fig. 7 A, B, C; for taurelated genes, see MAPT in Fig. 8A, B). Alternatively, the PGSs with significantly lower values in patients than in controls were positively correlated with MoCA total score in patients (i.e., for Aβ-related genes, see HLA-DRB1in Fig. 7A, B, C; for tau-related genes, see ADAMTS4 in Fig. 8A, B; for Aβ-and tau-related gene modules, see Fig. 4C, D). Similar relationships between the gene-to-pathology covariance (PGSs) and cognitive decline were observed using the MMSE instead of the MoCA in the ADNI cohort (see Supplement Table S3).</p>
<p>DISCUSSION</p>
<p>In this study, we confirmed the presence of distinctive spatial vulnerability patterns of Aβ and tau pathologies and identified their relationships to regional gene expression profiles of specific AD susceptibility genes and gene co-expression network modules. In addition, the identified gene-to-Aβ and gene-to-tau associations were related to distinct biochemical pathways. Moreover, we identified relationships between the gene-to-pathology (e.g., Aβ and tau) covariance and level of cognitive impairment in AD, which supports the clinical implication of understanding these Aβ-and tau-related gene-to-pathology associations. Of note, these findings were validated and successfully replicated using PET imaging data (for Aβ, AV45 vs. FBB; for tau, AV-1451) and two cognitive measures (MoCA vs. MMSE) from two large independent cohorts.</p>
<p>Previous studies suggested the significant roles of spatial MAPT 16 and APOE 17,24 expression profiles in facilitating brain-wide tau spreading in healthy aging. In line with these findings, we found that gene expression patterns of both MAPT and APOE were related to regional vulnerability to tau deposition in patients with MCI and AD compared to CU individuals. Of note, in addition to these consistent findings, our study also found that the positive APOE-to-tau association was specific to AD, whereas the positive MAPT-to-tau association was shared in both AD and FTLD patients, suggesting that there might be common genetic basis underlying the regional vulnerability of tauopathy. APOE has been frequently associated with Aβ pathology [25][26][27] , but seldom with tau pathology in human studies 28 (but see a mouse model study 29 ). Our study highlights the significant role of regional APOE expression pattern in relation to regional tau pathology. One recent study 30 found that APOE2 was related to lower regional tau burden, whereas APOE4 was related to higher regional tau deposit in Aβ positive CU, suggesting divergent effects of APOE2 and APOE4 on regional tau pathology in preclinical AD. The possible different spatial effects of APOE alleles (APOE2, APOE3, and APOE4) to tau pathology need to be considered in future studies.</p>
<p>In addition to MAPT and APOE, we identified novel positive and negative gene-to-tau associations for recently discovered AD risk genes from large GWAS studies. For instance, our finding of an AD-specific negative CD2AP gene-to-tau association agrees with the findings from a recent study 31 , where the CD2AP protein (a CD2associated scaffold protein) was found to be colocalized with phosphorylated tau in AD brains through immunofluorescence analysis. This study also found a strong and positive association between CD2AP immunodetection in neurons and Braak neurofibrillary tangle stage. Moreover, previous studies 32, 33 have reported a link between CD2AP expression and tau pathology as measured by cerebrospinal fluid (CSF) tau biomarkers. Finally, among all the tauopathy-related genes detected, the ADAMTS4 showed the strongest sex-independent gene-to-tau association in both AD and FTLD. It has been suggested that ADAMTS4, mainly expressed in oligodendrocytes, can produce strongly aggregating Aβ forms 34 , but only a few studies have found a direct relationship between the ADAMTS4 expression and tau pathology. Emerging research suggests that ADAMTS4 expression may have an indirect effect on tau production 35 . For instance, ADAMTS4 exhibits isoform-specific cleavage of Reelin, and the absence of Reelin has been linked to elevated tau phosphorylation and widespread formation of neurofibrillary tangles (NFTs 36,37 ). Finally, AGRN and PLD3 showed strong positive gene-to-tau associations in AD. However, the potential biological mechanisms underlying these brain-wide spatial associations remain unclear. The AGRN gene encodes the AGRIN protein, which plays important role in the regulation of axonal and dendritic growth 38 . One study 38 found that AGRIN upregulated the expression of tau and other microtubule-associated proteins in hippocampal neurons, suggesting a potential link between AGRN expression and tau pathology. The PLD3 gene encodes a lysosomal protein that is highly enriched in axonal spheroids in the hippocampus and cortex 39 . Of note, a recent study 40 observed that neuronal overexpression of All rights reserved. No reuse allowed without permission.</p>
<p>(which was not certified by peer review) is the author/funder, who has granted medRxiv a license to display the preprint in perpetuity.</p>
<p>The copyright holder for this preprint this version posted August 16, 2023. ; https://doi.org/10.1101/2023.08.12.23294017 doi: medRxiv preprint PLD3 affected axonal spheroids and induced neural circuit abnormalities in AD, while the deletion of PLD3 reduced endolysosomal vesicle accumulation and improved neural network function. Accumulating evidence 1, 41,42 suggests that tau protein spreads via neural circuits, the processing of which might be related to the neuronal overexpression of PLD3 40 . Although these identified tauopathy-related genes and corresponding geneto-tau associations are promising to advance our understanding of AD pathophysiology, future human and animal studies are required to validate our findings.</p>
<p>Findings of gene-to-Aβ associations are less convergent than those of gene-to-tau associations. One crosssectional study 15 found an APP-related gene-to-Aβ association, while another longitudinal study 16 reported a CLU-related gene-to-Aβ association. Our study found gene-to-Aβ associations with CLU and APP, as well as other newly discovered Aβ-related genes whose regional expression patterns are related to the regional vulnerability of Aβ pathology. In particular, CNTNAP2 and TMEM106B showed stronger positive gene-to-Aβ associations than CLU, APP, and other genes. Our findings are supported by previous studies. For example, one study 43 found that CNTNAP2 (a major gene in autism manifestation 44,45 ) expression was downregulated in the hippocampus of AD patients. Moreover, three recent studies [46][47][48] reported that amyloid fibrils in human brains, the main component of amyloid plaques, are formed by TMEM106B (a lysosomal/endosomal membrane protein), supporting our finding regarding the relationship between elevated TMEM106B expression and amyloid pathology. Of note, in addition to positive gene-to-Aβ associations identified by previous studies, we also found negative gene-to-Aβ associations, particularly involving regional INPP5D expression. Our previous studies 49,50 have reported that INPP5D expression was increased in late-onset AD and showed a positive correlation with amyloid plaque density. Preclinical studies in mice with INPP5D deficiency was sufficient to regulate microglial functions and reduce Aβ pathology 50 . However, the previous study with clinical samples was completed in multiple brain regions with only select regions having increased INPP5D expression 49 , suggesting that some regions may be more vulnerable than others. Furthermore, in the previous study, we separated MCI from AD samples, which may also have additional implications on the findings. Therefore, additional studies in mice may be needed to determine which areas of the brain have altered INPP5D expression and if that relates to amyloid deposition.</p>
<p>We observed sex-dependent differences in regional vulnerability to Aβ and tau pathologies, which are in line with recent findings [51][52][53][54][55][56] . Interestingly, these sex-dependent regional differences were only seen in negative gene-to-Aβ and gene-to-tau associations, but not positive associations. The potential biological mechanisms that might drive sex-dependent gene-to-pathology associations is unclear, although changes in endogenous or exogenous estrogen levels during menopausal stage in females might provide a possible explanation 52 . For instance, studies have linked Aβ 57-59 and tau 52,60 pathologies with changes in estrogen levels. Moreover, animal studies 61 have also found a direct relationship between tau vulnerability and estrogen depletion post-menopause. An alternative explanation may come from the sex differences in dysregulated immune responses 62 . Supporting this hypothesis, one study 63 found that microglial nuclei isolated from aged female donors exhibited an increased expression of AD risk genes, gene signatures associated with the inflammatory response in AD, and genes linked to proinflammatory immune responses, compared to microglial nuclei from male donors. Taken together, these findings indicate that the susceptibility of specific brain regions to Aβ and tau pathology may be influenced by both the sex-independent overexpression and sex-dependent under-expression of multiple genes and their associated regulatory processes.</p>
<p>Due to the polygenic nature of sporadic late-onset AD, accumulation of Aβ and tau pathologies is unlikely driven by regional expression patterns of individual AD risk genes. To test this hypothesis, we evaluated the joint contribution of multiple genes through two data-driven analyses using the whole AHBA gene data. Of note, we found that the discordance between the localization of Aβ and tau pathologies in the brain could be explained by average gene expression profiles of distinct gene co-expression network modules. On the one hand, the spatial vulnerability of Aβ pathology was related to a medial frontoparietal-dominant gene expression pattern. Notably, the medial frontoparietal regions are parts of the default mode network (DMN 5,64 ) derived from resting-state functional MRI data, which often show abnormal neural activity and connectivity in patients with AD 4,6,65,66 .</p>
<p>All rights reserved. No reuse allowed without permission.</p>
<p>(which was not certified by peer review) is the author/funder, who has granted medRxiv a license to display the preprint in perpetuity. Converging evidence indicates that Aβ initially accumulates in the medial frontoparietal DMN regions 1,67 . Therefore, our findings might provide a genetic basis for the colocalization of abnormal Aβ accumulation and abnormal DMN connectivity in AD. On the other hand, we found that spatial vulnerability of tau pathology was related to the regional expression patterns of three gene modules. It should be noted that a previous study 68 identified four distinct subtypes of tau accumulation patterns, some of which share similar spatial patterns with the expression patterns of the gene modules identified in the present study. Thus, one explanation could be that individuals with a specific tau accumulation subtype might be determined by the regional expression pattern of a specific gene module subtype. For instance, individuals with limbic-predominant tau pattern might have a cingulo-sensory-dominant gene expression profile, whereas individuals with posterior tau pattern might have a posterior occipitoparietal-dominant gene expression profile. These findings support our hypothesis that the regional average expression patterns of multiple genes (not only the individual AD susceptibility genes) might play vital roles in shaping the regional vulnerability patterns of Aβ and tau pathologies. Future studies are needed to test if the four subtypes of tau accumulation patterns are specifically related to the regional expression patterns of the four gene modules we identified in this study.</p>
<p>The GSEA results suggest that the positive and/or negative gene-to-Aβ and gene-to-tau associations at the levels of individual genes and gene modules are related to distinct biochemical pathways. Specifically, in line with previous studies, we found that the regional vulnerability to Aβ pathology was related to low expression levels of gene sets implicated in peptide antigen processing and transmembrane protein complex, whereas the regional vulnerability to tau pathology was associated with high expression levels of genes implicated in cytosolic ribosome, synaptic and postsynaptic functions, and axoneme assembly. The distinct biochemical pathways underlying the regional vulnerability to Aβ and tau pathologies might also explain the discordance between the localization of Aβ and tau pathologies in the brain 15,69-73 .</p>
<p>Since the development of the AHBA, a growing body of evidence suggests that specific regional gene expression profiles are related to brain structure and function in healthy subjects 13,74-90 and neuropathology-related abnormalities of brain structure and function in multiple neurological and neuropsychiatric disorders, such as frontotemporal dementia 91 , Parkinson's disease [92][93][94][95][96] , schizophrenia 97-100 , blind children 101 , early-life trauma 102 , major depression 83,103,104 , and autism 105 . However, these gene-to-connectivity or gene-to-pathology associations have not been translated to clinical utility. To fill this gap, the present study develops an innovative step forward by assessing the clinical significance of the identified gene-to-pathology associations in AD. Specifically, we developed an analytic framework characterizing individualized gene-to-pathology covariance that was related to cognitive dysfunction in patients with AD. Of note, not only can this framework aid in the translation of pathogenetic associations relevant to AD into clinical applications, but it can also be extended to understand cognitive function in healthy subjects and cognitive dysfunction in other brain disorders as mentioned above.</p>
<p>Some limitations of this study should be noted. First, our discoveries are primarily derived from correlation analyses, and as such, do not establish a causal relationship between gene expression patterns and the selective vulnerability of specific brain regions to Aβ and tau pathologies. Future studies using longitudinal designs may help identify possible causal relationships of these pathogenetic processes. Animal models could also be used to verify our findings. Second, the brain-wide gene expression data were measured postmortem in brains of six CU adults (aged 24-57 years; 5 males/1female) from the AHBA. To our knowledge, the AHBA is the only source of gene expression data currently available for brain-wide spatial association analysis. Future studies using age-and sex-matched individuals with CU aging or AD patients are required to replicate our findings. Last, the current study focuses on the detection of transcriptomic factors that contribute to the regional vulnerability of Aβ and tau pathologies, which cannot explain how Aβ and tau interact. Both human 106,107 and transgenic mice 108,109 studies have suggested that Aβ could remotely facilitate tau spreading from the MTL to other brain regions (e.g., the precuneus), possibly through long-range structural connections, leading to presumed downstream consequences, such as neurodegeneration and cognitive decline. However, it remains unknown if specific gene expression profiles might be playing a significant role in these pathological processes and if these processes might differ at different disease stages. Future studies leveraging longitudinal multimodal imaging data, including brain All rights reserved. No reuse allowed without permission.</p>
<p>(which was not certified by peer review) is the author/funder, who has granted medRxiv a license to display the preprint in perpetuity.</p>
<p>The copyright holder for this preprint this version posted August 16, 2023. ; https://doi.org/10.1101/2023.08.12.23294017 doi: medRxiv preprint connectivity, regional gene expression profiles, as well as Aβ and tau PET data, may be promising to resolve these important questions.</p>
<p>Overall, these results support the hypotheses that specific regional gene expression profiles are related to the selective regional vulnerability of deposition of Aβ and tau pathologies in AD, and that distinct biochemical pathways are involved in the gene-to-Aβ and gene-to-tau associations. Taken together, they support the corollary hypothesis 1,110,111 that gene transcription-associated regional vulnerability could explain the spatial discrepancies of Aβ and tau accumulation patterns that are observed in AD. Moreover, our findings highlight the clinical implication of the individualized gene-to-pathology associations in patients with AD, bridging the gap between pathogenetic mechanisms and clinical implication. The spatial gene-to-pathology associations and their relationships to cognitive decline in AD were replicated across two large independent datasets with different PET tracers and clinical measures. In the future, these findings and others may allow for forecasting and monitoring disease progression in individual patients, and ultimately help identify novel individualized pathogenetic biomarkers and therapeutic targets.</p>
<p>MATERIALS AND METHODS Study design</p>
<p>The main aim of this study is to identify relationships between regional gene expression profiles and regional vulnerability to Aβ and tau pathologies in AD. Leveraging two large AD datasets, the ADNI and the IMAS cohorts, we tested three hypotheses: 1) regional expression profiles of distinct individual genes and gene modules are associated with regional vulnerability to Aβ (gene-to-Aβ associations) and tau (gene-to-tau associations) pathologies; 2) distinct biochemical pathways are related to specific gene-to-Aβ and gene-to-tau associations; 3) the identified gene-to-Aβ and gene-to-tau associations are linked to cognitive dysfunction in individual AD patients. For both cohorts, participants were included based on availability of Aβ and tau PET and a structural T1-weighted MRI. All eligible participants from both observational studies were included in the analysis. Sample sizes were not predetermined in advance, and due to the nature of both cohorts, randomization of participants was not possible. In the ADNI cohort (http://adni.loni.usc.edu/), we included 583 participants (328 CU, 192 MCI, 25 AD) with Aβ PET data and 564 participants (312 CU, 190 MCI, 62 AD) with tau PET data. In the IMAS cohort, we included 110 participants (38 CU, 31 SCD, 30 MCI, 11AD) with Aβ PET data and 78 participants (30 CU, 20 SCD, 23 MCI, 5 AD) with tau PET data. We also included 11 patients with frontotemporal lobar degeneration (FTLD; 6 with behavioral variant FTD [bvFTD] and 5 with primary progressive aphasia [PPA]) from the Indiana Alzheimer's Disease Research Center (IADRC) cohort. We computed gene-to-tau associations for these FTLD patients and tested if the identified gene-to-tau associations were specific to AD or shared with FTLD. A multidisciplinary consensus meeting was held to make diagnoses. To be eligible for participation, individuals must not have an active psychiatric or neurological disorder. The specific inclusion/exclusion criteria for the ADNI cohort can be found at http://www.adni-info.org. The Indiana University Institutional Review Board approved the study, and written informed consent was obtained from each participant from both the IMAS and ADNI cohorts according to the Declaration of Helsinki.</p>
<p>Neurocognitive variables</p>
<p>All participants underwent a comprehensive clinical assessment and neuropsychological battery, as described in previous ADNI 112,113 and IMAS 114,115 studies. In this study, we used total scores of the Montreal Cognitive Assessment (MoCA) and the Mini-Mental State Exam (MMSE) for characterizing the cognitive function of participants and for the purpose of replicating results. Of note, the MoCA and the MMSE were used in the ADNI cohort, while only the MoCA was used in the IMAS cohort.</p>
<p>Image acquisition and preprocessing</p>
<p>Participants from both cohorts had an anatomical MRI with whole brain coverage using a 3D Magnetization Prepared Rapid Gradient Echo (MPRAGE) sequence (220 sagittal slices, 1.1  1.1  1.2mm 3 voxels) per the Alzheimer's Disease Neuroimaging Initiative (ADNI-2) imaging protocol. In the IMAS cohort, we implemented an accelerated protocol (GRAPPA, R=2) to reduce imaging time from 9:14 s (IMAS dataset) to 5:12 s. All the All rights reserved. No reuse allowed without permission.</p>
<p>(which was not certified by peer review) is the author/funder, who has granted medRxiv a license to display the preprint in perpetuity.</p>
<p>The copyright holder for this preprint this version posted August 16, 2023. ; https://doi.org/10.1101/2023.08.12.23294017 doi: medRxiv preprint T1-weighted images were preprocessed using FreeSurfer v6.0 (https://surfer.nmr.mgh.harvard.edu/) as previously described [116][117][118] .</p>
<p>Aβ and tau PET imaging preprocessing</p>
<p>All participants from the IMAS and ADNI had two PET imaging acquisitions: (1) [ 18 F]flortaucipir (18F-AV-1451) PET scan, a tracer that binds to tau in neurofibrillary tangles and neurites; and, (2) one of two amyloid PET tracers, [ 18 F]florbetapir (AV45) or [ 18 F]florbetaben (FBB) that bind to fibrillary Aβ plaques. The ADNI Aβ and tau PET data were processed by Dr. William Jagust's lab [119][120][121][122] and were downloaded from the publicly available database at the Laboratory of Neuro Imaging (LONI) Image &amp; Data Archive (IDA) Repository (https://ida.loni.usc.edu/). Briefly, each Aβ PET scan was co-registered to the MRI closest in time. A native-space MRI scan for each subject is processed (segmentation and parcellation) with FreeSurfer version 6 to define a cortical summary region. The cortical summary region consists of frontal, anterior/posterior cingulate, lateral parietal, and lateral temporal regions. Summary SUVRs were calculated by normalizing the cortical summary region by the FreeSurfer-defined whole cerebellum (a reference region) with a positivity threshold of 1.11 for the [ 18 F]florbetapir SUVRs and a positivity threshold of 1.08 for the [ 18 F]florbetaben SUVRs. Similar processing procedures were applied when generating summary Flortaucipir SUVRs with Braak stage composite regions as the cortical summary region and inferior cerebellar gray matter as the reference region 123,124 . Partial volume correction (PVC) was not applied to the [ 18 F]flortaucipir SUVRs, as previous studies have rarely found PVCrelated effects in gene-to-tau associations 16,17 .</p>
<p>The details of IMAS PET data processing analyses were described in previous studies 116,125,126 . PET data were reconstructed using an ordered subset expectation maximization algorithm with weighted attenuation following Siemens manufacturers protocols. Using SPM12, all PET data in native space were corrected for motion, coregistered to their corresponding T1-weighted MRI images, and spatially normalized into MNI152 template using normalization parameters obtained from the T1-weighted MRI normalization. Static images from 50-70 minutes or 90-110 minutes were created as the sum of appropriate time frames for [ 18 F]florbetapir or [ 18 F]florbetaben, respectively. Static images were intensity normalized to the whole cerebellum to create standardized uptake value ratio (SUVR) images. For [ 18 F]flortaucipir, static images were created from 80-100 minutes post-injection and intensity normalized to the cerebellar crus to create SUVR images. Finally, all PET scans were smoothed with an 8mm full width half maximum Gaussian kernel. Median Aβ and tau PET SUVR values were extracted from FreeSurfer's Desikan-Killiany (D-K) atlas defined 68 cortical regions 127 . Aβ positivity was defined as a SUVR &gt; 1.1 for [ 18 F]florbetapir and SUVR &gt; 1.2 for [ 18 F]florbetaben. Continuous variables for PET images were used in the subsequent association analysis.</p>
<p>Regional transcriptional analysis</p>
<p>Regional gene expression profiles for 20,736 protein-coding genes were derived from brain-wide microarraybased transcriptome data from the Allen Human Brain Atlas 11,12 . The microarray probes were collected from 3,700 regional brain tissue samples in autopsy data of six adult individuals (5 males/1 female; aged 24-57 years) without history of neurological disorders. Of note, as the first two donors (1 male and 1 female) did not show interhemispheric asymmetries and sex-related differences in gene expression data, the subsequent four donors (all males) had brain tissue collection in the left hemisphere only. A recommended analysis pipeline 14,128 was used to preprocess the gene expression data in the left hemisphere, including probe-to-gene re-annotation, data filtering, probe selection, sample assignment, gene filtering, and normalization across the 6 donors. Specifically, the following probe filtering criteria were applied: i) the probe-to-gene annotations were updated using Re-Annotator package; ii) the reannotated probes with expression measures lower than the background in more than 50% samples were discarded; iii) a representative probe with the highest intensity was selected to represent a gene. This procedure retained 15,745 probes, each representing a unique protein-coding gene. Gene expression values were normalized separately for each donor across cortical regions and then averaged across donors. The D-K atlas was used to parcellate each gene expression map into 34 cortical regions in the left hemisphere. Of note, we used the D-K atlas to define the same cortical regions for both the PET and gene expression imaging data. Based on the hemispheric symmetry of gene expression patterns, the left hemisphere regional gene expression values for All rights reserved. No reuse allowed without permission.</p>
<p>(which was not certified by peer review) is the author/funder, who has granted medRxiv a license to display the preprint in perpetuity.</p>
<p>The copyright holder for this preprint this version posted August 16, 2023. ; https://doi.org/10.1101/2023.08.12.23294017 doi: medRxiv preprint each gene were mirrored to the right hemisphere 17 , resulting in gene expression values of 68 cortical regions for each gene. Finally, a gene expression matrix (15,745 × 68) was constructed, where rows of the matrix correspond to the 15,745 genes and columns correspond to 68 cortical regions.</p>
<p>Hypothesis-driven analysis Candidate gene analysis</p>
<p>We tested the mechanistic hypothesis that the regional vulnerability to Aβ and tau pathologies are spatially correlated with regional expression levels of AD candidate genes associated with Aβ and tau pathology. As a first step, we estimated the regional vulnerability to Aβ and tau pathologies by contrasting Aβ and tau PET imaging data between cognitively normal participants (CU in the ADNI cohort; CU and SCD in the IMAS cohort) and patients (MCI and AD in two cohorts) using independent samples T-test. The similarities of regional vulnerability to Aβ and tau pathologies between the ADNI and IMAS cohorts were estimated by computing Pearson's correlations between the T-statistic scores of the two cohorts. Then, we computed spatial associations between regional gene expression levels and regional vulnerability to Aβ (gene-to-Aβ associations) and tau (gene-to-tau associations) pathologies (represented as case-control T-statistic maps), for 60 AD susceptibility genes selected from recent large-scale GWAS studies [18][19][20] . Following preprocessing, 15 genes were excluded due to not meeting the quality control criteria outlined above, resulting in 45 out of the initial 60 genes being eligible for candidate gene analysis. The Benjamini-Hochberg's False Discovery Rate (B-H FDR) correction ( FDR &lt; 0.05) was used to control for false positive results caused by multiple comparisons.</p>
<p>Spatial permutation test (spin test)</p>
<p>Recent studies 129 have found that statistical significance of spatial correlations between imaging maps could be inflated by failing to consider the spatial autocorrelation effects: neighboring data points are unlikely statistically independent. In this study, we use Vasa's spin test method 130 to control for the inherent spatial autocorrelation effects in the PET imaging and transcriptomic data. Briefly, a spatial permutation framework was used to generate null spatial models by randomly spinning (or rotating; number of rotations = 10,000) the spherical representations of the parcellated cortical map (e.g., D-K atlas) and preserving the spatial relationships across brain regions 131 . The reconstructed gene expression data were used to generate a null distribution of correlation coefficients, which were then used to evaluate if the observed spatial correlations exceed the expected null spatial correlations estimated by using randomized brain regions with the same neighboring relationships.</p>
<p>Gene specificity test</p>
<p>We assessed the gene specificity by comparing the observed spatial gene-to-Aβ and gene-to-tau associations to a null distribution of associations estimated by other sets of genes 132 . Specifically, we constructed a null model to test if the observed associations will be stronger than the null distribution of associations estimated by randomly selected background genes that are significantly overexpressed in the brain tissues than in other body sites.</p>
<p>Pathology specificity analysis</p>
<p>We assessed if the regional vulnerability to tau pathology and its relation to regional gene expression profiles were specific to AD or shared with frontotemporal lobar degeneration (FTLD), a different dementia type sometimes characterized by tauopathy [133][134][135][136][137] . Specifically, we included 11 patients with FTLD (6 with behavioral variant FTD [bvFTD] and 5 with primary progressive aphasia [PPA]) from the IADRC cohort and added 11 FTLD risk genes 138-144 (e.g ., C9orf72, GRN, FUS, KIAA0319, VCP, TARDBP, CHMP2B, ITM2B, TBK1, TBP, CTSF) to the analysis. We then reconducted the regional tau PET analysis and regional transcriptional analysis as described above.</p>
<p>Sex specificity analysis</p>
<p>Previous studies reported sex-dependent differences in regional vulnerability to Aβ 58,59 and tau [51][52][53]55,60 pathologies. To assess the potential effects of sex on the identified spatial gene-to-Aβ and gene-to-tau associations, we recomputed the regional vulnerability to tau pathology and its relation to regional gene expression profiles in All rights reserved. No reuse allowed without permission.</p>
<p>(which was not certified by peer review) is the author/funder, who has granted medRxiv a license to display the preprint in perpetuity.</p>
<p>The copyright holder for this preprint this version posted August 16, 2023. ; https://doi.org/10.1101/2023.08.12.23294017 doi: medRxiv preprint males and females, separately. Due to sample size issues, we focus on the ADNI Aβ and tau data when conducting the sex specificity analysis.</p>
<p>Data-driven analysis Gene co-expression network analysis</p>
<p>Genes often show correlated spatial expression pattens, indicating that they do not function independently 11,12,77,145 . Thus, going beyond hypothesis-driven analysis using a prior set of selected individual AD candidate genes, we performed a data-driven analysis linking the regional vulnerability to Aβ and tau pathologies with average expression profiles of gene co-expression modules consisting of hundreds or thousands of genes. Specifically, we first constructed a weighted gene co-expression network (15,745 × 15,745) by computing Pearson's correlations between the regional expression profiles for pairs of the 15,745 genes. In this gene co-expression network, each gene is a node and each link between two nodes is the Pearson correlation between the regional expression profiles of each pair of genes. The correlation coefficients were then Fisher r-toz transformed. Next, we used the Louvain's community detection method 22 (gamma = 1.5; symmetric treatment of negative weights) and a consensus clustering algorithm 23 ( = 0.4; repetition times = 50) implemented in the Brain Connectivity Toolbox 146,147 to identify consensus gene co-expression modules (or clusters). Of note, we included links with both positive and negative values into the community detection analysis, as previous gene coexpression studies [148][149][150] demonstrated the existence of negatively correlated gene expression, suggesting the equal importance of both positive and negative link weights in gene co-expression network. Subsequently, we estimated the average gene expression level for each gene co-expression module, and then computed gene-topathology associations between regional gene expression levels for each module and the regional vulnerability to Aβ and tau pathologies, respectively.</p>
<p>Gene set enrichment analysis</p>
<p>In a secondary data-driven analysis, we performed gene set enrichment analysis (GSEA 151,152 ) to identify biochemical pathways of gene sets with expression patterns associated with the regional vulnerability to Aβ and tau pathologies. We used gene sets involved in biological processes and cellular component functions that group genes using annotations from Gene Ontology (GO 153 ). First, we calculated spatial correlations between genomewide regional expression profiles of all the 15,745 genes and the regional vulnerability to Aβ and tau pathologies, respectively. Next, we ranked the 15,745 genes according to their spatial correlation values: the top (positive correlations) and bottom parts (negative correlations) of this ranked list contain the genes of interest, expression values of which increase or decrease, respectively, in relation to the regional vulnerability to Aβ or tau pathologies. Then, GSEAPreranked analysis was performed against the ranked genes using the GSEA software (version 4.3.2). The normalized enrichment score was computed to quantify the non-random distribution of a gene set in a ranked list, while also taking into consideration the varying sizes of the functional gene sets being analyzed. Permutation testing (1000 permutations) was used to assess statistical significance. FDR correction ( FDR &lt; 0.05) was used to control for the independent testing of multiple gene sets. Finally, we performed a leading-edge analysis to analyze commonalities among the most relevant genes of the identified pathways by clustering the respective leadingedge gene subsets, the principal genes that account for a gene set's enrichment signal.</p>
<p>Clinical implication of gene-to-pathology associations</p>
<p>We developed a novel analytic framework for assessing the clinical implication of the identified gene-to-Aβ and gene-to-tau associations. Specifically, for the ADNI [ 18 F]florbetapir data, we first computed covariance values between regional gene expression values for each AD candidate gene and individualized regional Aβ deposition values across all the individuals, resulting in individual-level gene-to-Aβ covariance values, named as Aβ-related pathogenetic scores (PGSs). Then, we estimated group differences of the Aβ-related PGSs between patients (MCI and AD) and cognitively normal controls (CU and/or SCD). Next, for the genes showing significantly different Aβ-related PGSs between groups ( FDR &lt; 0.05), we computed Pearson's correlations between the PGSs and MoCA total score. This analytic framework links the gene-to-pathology (Aβ or tau) associations with cognitive dysfunction in AD, characterizing the clinical implication of gene-to-pathology associations. To assess their reproducibility, the PGSs and their correlations to MoCA performance were calculated for other Aβ (e.g., the All rights reserved. No reuse allowed without permission.</p>
<p>(which was not certified by peer review) is the author/funder, who has granted medRxiv a license to display the preprint in perpetuity.</p>
<p>The copyright holder for this preprint this version posted August 16, 2023. ; https://doi.org/10.1101/2023.08.12.23294017 doi: medRxiv preprint ADNI FBB and IMAS Aβ data) and for tau (e.g., ADNI and IMAS tau data) data. The PGSs and their correlations to MoCA performance were calculated for both AD candidate genes and gene modules identified by gene coexpression network analysis. As the ADNI cohort also has MMSE data, we validated the relationships between the gene-to-pathology (e.g., Aβ and tau) covariance (PGCSs) and cognitive decline measured by MMSE total score in the ADNI AD patients.</p>
<p>Statistical analysis</p>
<p>Statistical analyses of subject characteristics were performed with jamovi (version: 2.3.21; https://www.jamovi.org/download.html). Group differences in age, MoCA, and MMSE were tested using oneway ANOVA tests, while sex differences between groups were tested using a chi-square ( 2 ) test. Other statistical analyses were described detail above. Table S1. Gene-to-Aβ and gene-to-tau associations accounting for the effects of spatial autocorrelation and gene specificity. Table S2. Negatively and positively enriched gene sets identified by the GSEA. Table S3. Relationships between the gene-to-pathology covariance and cognitive dysfunction measured by MoCA and MMSE, respectively. Figure S1. Spatial gene-to-tau associations between brain-wide gene expression profiles of AD/FTD susceptibility genes and brain-wide tau PET data in the IMAS cohort. Figure S2. Spatial gene-to-Aβ associations between brain-wide gene expression profiles and brainwide Aβ data measured in the males and females, separately. Figure S3. Spatial gene-to-tau associations between brain-wide gene expression profiles and brainwide tau data measured in the males and females, separately. In a hypothesis-driven analysis, we computed spatial gene-to-pathology associations between brain-wide gene expression profiles of 45 AD susceptibility genes and regional vulnerability to Aβ as well as tau pathologies. We then performed two data-driven analyses (B, C) using regional gene expression profiles of all the 15,745 AHBA genes. (B) We constructed a gene co-expression network, where nodes represent genes and links denote correlations between expression profiles of 15,745 genes. We then identified 4 gene modules and compute spatial associations between average gene expression profiles of the 4 gene modules and regional vulnerability to Aβ as well as tau pathologies. (C) We computed spatial associations between brain-wide gene expression profiles of 15,745 genes and regional vulnerability to Aβ as well as tau pathologies. We then used the GSEA software to conduct GSEAPreranked analysis on the ranked spatial correlations and identified enriched gene sets. (D)</p>
<p>SUPPLEMENTARY MATERIALS Supplement</p>
<p>Supplement</p>
<p>Supplement</p>
<p>Supplement</p>
<p>Supplement</p>
<p>Supplement</p>
<p>We computed personalized spatial gene-to-pathology associations between brain-wide gene expression profiles of 45 AD susceptibility genes and individualized regional Aβ and tau pathologies, resulting in individual-level Aβand tau-related pathogenetic scores (PGSs). Then, we estimated group differences of PGSs between patients (MCI and AD) and controls (CU and/or SCD) for each gene. Finally, for the genes showing significantly different PGSs between groups, we computed Pearson's correlations between the PGSs and cognitive scores (e.g., MoCA and MMSE). The above analyses (A-D) were performed using both the ADNI (discovery) and IMAS (replication) datasets. Analysis All rights reserved. No reuse allowed without permission.</p>
<p>(which was not certified by peer review) is the author/funder, who has granted medRxiv a license to display the preprint in perpetuity.  All rights reserved. No reuse allowed without permission.</p>
<p>(which was not certified by peer review) is the author/funder, who has granted medRxiv a license to display the preprint in perpetuity.  All rights reserved. No reuse allowed without permission.</p>
<p>(which was not certified by peer review) is the author/funder, who has granted medRxiv a license to display the preprint in perpetuity.</p>
<p>The copyright holder for this preprint this version posted August 16, 2023. ; https://doi.org/10.1101/2023.08.12.23294017 doi: medRxiv preprint Spatial gene-to-Aβ and gene-to-tau associations (B) between average regional gene expression profiles of the four gene modules and regional vulnerability to Aβ and tau pathologies across the two cohorts: ADNI (AV45), ADNI (FBB), IMAS (AV45/FBB), ADNI tau (1AV451), and IMAS tau (1AV451). P-values were log10 transformed in (B). Group differences of pathogenetic scores (PGSs) between patients and All rights reserved. No reuse allowed without permission.</p>
<p>(which was not certified by peer review) is the author/funder, who has granted medRxiv a license to display the preprint in perpetuity.</p>
<p>The copyright holder for this preprint this version posted August 16, 2023. ; https://doi.org/10.1101/2023.08.12.23294017 doi: medRxiv preprint controls and their relationships to cognitive dysfunction in AD for the Aβ (C) and tau (D) pathologies, respectively. Abbreviations: AD = Alzheimer's disease; IMAS = Indiana Memory and Aging Study; ADNI = Alzheimer's Disease Neuroimaging Initiative; AV1451 = [ 18   All rights reserved. No reuse allowed without permission.</p>
<p>(which was not certified by peer review) is the author/funder, who has granted medRxiv a license to display the preprint in perpetuity.</p>
<p>The copyright holder for this preprint this version posted August 16, 2023. ; https://doi.org/10.1101/2023.08.12.23294017 doi: medRxiv preprint All rights reserved. No reuse allowed without permission.</p>
<p>(which was not certified by peer review) is the author/funder, who has granted medRxiv a license to display the preprint in perpetuity.</p>
<p>The copyright holder for this preprint this version posted August 16, 2023. ; https://doi.org/10.1101/2023.08.12.23294017 doi: medRxiv preprint  (which was not certified by peer review) is the author/funder, who has granted medRxiv a license to display the preprint in perpetuity.</p>
<p>The copyright holder for this preprint this version posted August 16, 2023. ; https://doi.org/10.1101/2023.08.12.23294017 doi: medRxiv preprint (AV1451) (B). Abbreviations: CU = cognitively unimpaired; SCD = subjective cognitive decline; MCI = mild cognitive impairment; AD = Alzheimer's disease; IMAS = Indiana Memory and Aging Study; ADNI = Alzheimer's Disease Neuroimaging Initiative; AV1451 = [ 18 F]flortaucipir. </p>
<p>Figure 1 .
1Schematic overview of the applied methods. (A)</p>
<p>(D) was also performed using average expression profiles of 4 gene modules identified in analysis (B). Abbreviations: CU = cognitively unimpaired; SCD = subjective cognitive decline; MCI = mild cognitive impairment; AD = Alzheimer's disease; IMAS = Indiana Memory and Aging Study; ADNI = Alzheimer's Disease Neuroimaging Initiative; MoCA = Montreal Cognitive Assessment; MMSE = Mini-Mental State Exam; GSEA = gene set enrichment analysis.</p>
<p>Figure 2 .
2(A) Spatial patterns for Aβ deposits (SUVR values) across diagnosis groups and T-statistics map for regional differences. (B) Spatial gene-to-Aβ associations between brain-wide gene expression profiles of 45 AD susceptibility genes selected from recent large-scale GWAS studies and brain-wide Aβ data measured by two PET tracers in the IMAS and ADNI cohorts, separately.P-values were log10 transformed in (B). Abbreviations: A = anterior; P = posterior; RH = right hemisphere; LH = left hemisphere; CU = cognitively unimpaired; SCD = subjective cognitive decline; MCI = mild cognitive impairment; AD = Alzheimer's disease; IMAS = Indiana Memory and Aging Study; ADNI = Alzheimer's Disease Neuroimaging Initiative; AV45 = [18F]florbetapir; FBB = [18F]florbetaben.</p>
<p>Figure 3 .
3(A) Spatial patterns for tau deposits (SUVR values) across diagnosis groups and T-statistics map for regional differences. (B) Spatial gene-to-tau associations between brain-wide gene expression profiles of 60 AD susceptibility genes selected from recent large-scale GWAS studies and brain-wide tau PET data in the IMAS and ADNI cohorts, separately.P-values were log10 transformed in (B). Abbreviations: A = anterior; P = posterior; RH = right hemisphere; LH = left hemisphere; CU = cognitively unimpaired; SCD = subjective cognitive decline; MCI = mild cognitive impairment; AD = Alzheimer's disease; IMAS = Indiana Memory and Aging Study; ADNI = Alzheimer's Disease Neuroimaging Initiative; AV1451 = [ 18 F]flortaucipir.</p>
<p>Figure 4 .
4Four gene modules identified in the gene co-expression network showing distinct spatial patterns (A).</p>
<p>Figure 5 .
5Enrichment plots for genes that were negatively associated with the gene-to-Aβ association across the two cohorts: ADNI (AV45) (A), ADNI (FBB) (B), and IMAS (AV45/FBB) (C). Abbreviations: MAS = Indiana Memory and Aging Study; ADNI = Alzheimer's Disease Neuroimaging Initiative; AV45 = [ 18 F]florbetapir; FBB = [ 18 F]florbetaben.</p>
<p>Figure 6 .
6Enrichment plots for genes that were positively associated with the gene-to-tau association across the two cohorts: ADNI (AV1451) (A) and IMAS (AV1451) (B). Abbreviations: IMAS = Indiana Memory and Aging Study; ADNI = Alzheimer's Disease Neuroimaging Initiative; AV1451 = [ 18 F]flortaucipir.</p>
<p>Figure 7 .
7Group differences of Aβ-related pathogenetic scores (PGSs) between patients and controls and their relationships to cognitive dysfunction in AD across the two cohorts: ADNI (AV45) (A), ADNI (FBB) (B), and IMAS (AV45/FBB) (C). Abbreviations: CU = cognitively unimpaired; SCD = subjective cognitive decline; MCI = mild cognitive impairment; AD = Alzheimer's disease; IMAS = Indiana Memory and Aging Study; ADNI = Alzheimer's Disease Neuroimaging Initiative; AV45 = [18F]florbetapir; FBB = [18F]florbetaben.</p>
<p>Figure 8 .
8Group differences of tau-related pathogenetic scores (PGSs) between patients and controls and their relationships to cognitive dysfunction in AD across the two cohorts: ADNI (AV1451) (A) and IMAS All rights reserved. No reuse allowed without permission.</p>
<p>The copyright holder for this preprint this version posted August 16, 2023. ; https://doi.org/10.1101/2023.08.12.23294017 doi: medRxiv preprint</p>
<p>The copyright holder for this preprint this version posted August 16, 2023. ; https://doi.org/10.1101/2023.08.12.23294017 doi: medRxiv preprint</p>
<p>Table 1 .
1Characteristics of ADNI and IMAS samples. n = sample size; F = female; M = male; MoCA = Montreal Cognitive Assessment; MMSE = Mini-Mental State Exam; CU = cognitively unimpaired; SCD = subjective cognitive decline; MCI = mild cognitive impairment; AD = Alzheimer's disease; P = P values; n.a. = not available. One-way ANOVA tests (for age, MoCA and MMSE) or chi-square ( 2 ) tests (for sex) were used when applicable. Age, MoCA and MMSE scores are presented as mean and standard deviation.ADNI 
IMAS 
CU 
MCI 
AD 
P 
CU 
SCD 
MCI 
AD 
P 
n 
336 
200 
69 
n.a. 
38 
31 
30 
11 
n.a. 
Age 
70.1 ± 
6.81 </p>
<p>71.7 ± 
7.43 </p>
<p>74.2 ± 
8.50 </p>
<p>&lt; .001 71.1 ± 
6.19 </p>
<p>70.9 ± 
6.96 </p>
<p>73.8 ± 
7.11 </p>
<p>71.9 ± 
7.34 </p>
<p>.35 </p>
<p>Sex (F/M) 
198/138 94/106 322/283 &lt; .001 29/9 
17/14 
15/15 
7/4 
.12 
MoCA 
26.0 ± 
2.72 </p>
<p>22.8 ± 
3.40 </p>
<p>16.5 ± 
4.41 </p>
<p>&lt; .001 26.4 ± 
2.03 </p>
<p>25.9 ± 
2.53 </p>
<p>20.5 ± 
4.02 </p>
<p>13.7 ± 
4.61 </p>
<p>&lt; .001 </p>
<p>MMSE 
29.1 ± 
1.05 </p>
<p>27.7 ± 
2.05 </p>
<p>22.8 ± 
2.77 </p>
<p>&lt; .001 n.a. 
n.a. 
n.a. 
n.a. 
n.a. </p>
<p>All rights reserved. No reuse allowed without permission.(which was not certified by peer review) is the author/funder, who has granted medRxiv a license to display the preprint in perpetuity.The copyright holder for this preprint this version postedAugust 16, 2023.  ;   https://doi.org/10.1101/2023.08.12.23294017 doi: medRxiv preprint
Competing interests: See details in Declaration of Interests form.Data and materials availability: All the data associated with this study are present either in the paper or in the Supplementary Materials. ADNI data are available online after signing a data use agreement. The IMAS data management is overseen by A.J.S. and S.R. at the Indiana Alzheimer's Disease Research Center (IADRC).
The human connectome in Alzheimer disease -relationship to biomarkers and genetics. M Yu, O Sporns, A J Saykin, Nat Rev Neurol. 17Yu, M., Sporns, O. &amp; Saykin, A. J. The human connectome in Alzheimer disease -relationship to biomarkers and genetics. Nat Rev Neurol 17, 545-563 (2021).</p>
<p>Imaging the evolution and pathophysiology of Alzheimer disease. W Jagust, Nat Rev Neurosci. 1911Jagust, W. Imaging the evolution and pathophysiology of Alzheimer disease. Nat Rev Neurosci 19(11), 687-700 (2018).</p>
<p>Biomarkers for neurodegenerative diseases. O Hansson, Nat Med. 27Hansson, O. Biomarkers for neurodegenerative diseases. Nat Med 27, 954-963 (2021).</p>
<p>Earliest accumulation of β-amyloid occurs within the default-mode network and concurrently affects brain connectivity. S Palmqvist, Nat Commun. 81214Palmqvist, S. et al. Earliest accumulation of β-amyloid occurs within the default-mode network and concurrently affects brain connectivity. Nat Commun 8, 1214 (2017).</p>
<p>The brain's default network: updated anatomy, physiology and evolving insights. R L Buckner, L M Dinicola, Nat Rev Neurosci. 20Buckner, R. L. &amp; DiNicola, L. M. The brain's default network: updated anatomy, physiology and evolving insights. Nat Rev Neurosci 20, 593-608 (2019).</p>
<p>Amyloid Deposition Is Associated with Impaired Default Network Function in Older Persons without Dementia. R A Sperling, Neuron. 63Sperling, R. A. et al. Amyloid Deposition Is Associated with Impaired Default Network Function in Older Persons without Dementia. Neuron 63, 178-188 (2009).</p>
<p>Longitudinal tau PET in ageing and Alzheimer's disease. C R Jack, Brain. 141Jack, C. R. et al. Longitudinal tau PET in ageing and Alzheimer's disease. Brain 141, 1517-1528 (2018).</p>
<p>Prospective longitudinal atrophy in Alzheimer ' s disease correlates with the intensity and topography of baseline tau-PET. R Joie, La, Sci Transl Med. 125732Joie, R. La et al. Prospective longitudinal atrophy in Alzheimer ' s disease correlates with the intensity and topography of baseline tau-PET. Sci Transl Med 12, eaau5732 (2020).</p>
<p>Structural tract alterations predict down-stream tau accumulation in amyloid positive older individuals. H I L Jacobs, Nat Neurosci. 21Jacobs, H. I. L. et al. Structural tract alterations predict down-stream tau accumulation in amyloid positive older individuals. Nat Neurosci 21, 424-431 (2018).</p>
<p>Tau biomarkers in Alzheimer's disease: towards implementation in clinical practice and trials. R Ossenkoppele, R Van Der Kant, O Hansson, Lancet Neurol. 21Ossenkoppele, R., van der Kant, R. &amp; Hansson, O. Tau biomarkers in Alzheimer's disease: towards implementation in clinical practice and trials. Lancet Neurol 21, 726-734 (2022).</p>
<p>An anatomically comprehensive atlas of the adult human brain transcriptome. M J Hawrylycz, Nature. 489Hawrylycz, M. J. et al. An anatomically comprehensive atlas of the adult human brain transcriptome. Nature 489, 391-399 (2012).</p>
<p>Canonical genetic signatures of the adult human brain. M Hawrylycz, Nat Neurosci. 18Hawrylycz, M. et al. Canonical genetic signatures of the adult human brain. Nat Neurosci 18, 1832-1844 (2015).</p>
<p>Bridging the Gap between Connectome and Transcriptome. A Fornito, A Arnatkevičiūtė, B D Fulcher, Trends Cogn Sci. 23Fornito, A., Arnatkevičiūtė, A. &amp; Fulcher, B. D. Bridging the Gap between Connectome and Transcriptome. Trends Cogn Sci 23, 34-50 (2019).</p>
<p>Toward Best Practices for Imaging Transcriptomics of the Human Brain. A Arnatkeviciute, R D Markello, B D Fulcher, B Misic, A Fornito, Biol Psychiatry. 93Arnatkeviciute, A., Markello, R. D., Fulcher, B. D., Misic, B. &amp; Fornito, A. Toward Best Practices for Imaging Transcriptomics of the Human Brain. Biol Psychiatry 93, 391-404 (2023).</p>
<p>Molecular properties underlying regional vulnerability to Alzheimer's disease pathology. M J Grothe, Brain. 141Grothe, M. J. et al. Molecular properties underlying regional vulnerability to Alzheimer's disease pathology. Brain 141, 2755-2771 (2018).</p>
<p>Neurogenetic contributions to amyloid beta and tau spreading in the human cortex. J Sepulcre, Nat Med. 24Sepulcre, J. et al. Neurogenetic contributions to amyloid beta and tau spreading in the human cortex. Nat Med 24, 1910-1918 (2018).</p>
<p>Network Tau spreading is vulnerable to the expression gradients of APOE and glutamatergic-related genes. V Montal, Sci. Transl. Med. 147273Montal, V. et al. Network Tau spreading is vulnerable to the expression gradients of APOE and glutamatergic-related genes. Sci. Transl. Med 14, eabn7273 (2022).</p>
<p>Genome-wide meta-analysis identifies new loci and functional pathways influencing Alzheimer's disease risk. I E Jansen, Nat Genet. 51Jansen, I. E. et al. Genome-wide meta-analysis identifies new loci and functional pathways influencing Alzheimer's disease risk. Nat Genet 51, 404-413 (2019).</p>
<p>Genetic meta-analysis of diagnosed Alzheimer's disease identifies new risk loci and implicates Aβ, tau, immunity and lipid processing. B W Kunkle, Nat Genet. 51Kunkle, B. W. et al. Genetic meta-analysis of diagnosed Alzheimer's disease identifies new risk loci and implicates Aβ, tau, immunity and lipid processing. Nat Genet 51, 414-430 (2019).</p>
<p>New insights into the genetic etiology of Alzheimer's disease and related dementias. C Bellenguez, Nat Genet. 54Bellenguez, C. et al. New insights into the genetic etiology of Alzheimer's disease and related dementias. Nat Genet 54, 412-436 (2022).</p>
<p>Gene set enrichment analysis: A knowledge-based approach for interpreting genome-wide expression profiles. A Subramanian, Proc Natl Acad Sci U S A. 102Subramanian, A. et al. Gene set enrichment analysis: A knowledge-based approach for interpreting genome-wide expression profiles. Proc Natl Acad Sci U S A 102, 15545-15550 (2005).</p>
<p>Fast unfolding of communities in large networks. V D Blondel, J.-L L Guillaume, R Lambiotte, E Lefebvre, Journal of Statistical Mechanics: Theory and Experiment. Blondel, V. D., Guillaume, J.-L. L., Lambiotte, R. &amp; Lefebvre, E. Fast unfolding of communities in large networks. Journal of Statistical Mechanics: Theory and Experiment 2008, 1-12 (2008).</p>
<p>Consensus clustering in complex networks. A Lancichinetti, S Fortunato, Sci Rep. 2Lancichinetti, A. &amp; Fortunato, S. Consensus clustering in complex networks. Sci Rep 2, (2012).</p>
<p>APOE ε4 genotype, amyloid-β, and sex interact to predict tau in regions of high APOE mRNA expression. A Dincer, Sci Transl Med. 1476Dincer, A. et al. APOE ε4 genotype, amyloid-β, and sex interact to predict tau in regions of high APOE mRNA expression. Sci Transl Med 14, eabl76 (2022).</p>
<p>A Quarter Century of APOE and Alzheimer's Disease: Progress to Date and the Path Forward. M E Belloy, V Napolioni, M D Greicius, Neuron. 101Belloy, M. E., Napolioni, V. &amp; Greicius, M. D. A Quarter Century of APOE and Alzheimer's Disease: Progress to Date and the Path Forward. Neuron 101, 820-838 (2019).</p>
<p>Apolipoprotein E: Structural Insights and Links to Alzheimer Disease Pathogenesis. Y Chen, M R Strickland, A Soranno, D M Holtzman, Neuron. 109Chen, Y., Strickland, M. R., Soranno, A. &amp; Holtzman, D. M. Apolipoprotein E: Structural Insights and Links to Alzheimer Disease Pathogenesis. Neuron 109, 205-221 (2021).</p>
<p>ApoE Cascade Hypothesis in the pathogenesis of Alzheimer's disease and related dementias. Y A Martens, 10.1016/j.neuron.2022.03.004Neuron. 110Martens, Y. A. et al. ApoE Cascade Hypothesis in the pathogenesis of Alzheimer's disease and related dementias. Neuron vol. 110 1304-1317 Preprint at https://doi.org/10.1016/j.neuron.2022.03.004 (2022).</p>
<p>APOE predicts amyloid-beta but not tau Alzheimer pathology in cognitively normal aging. J C Morris, Ann Neurol. 67Morris, J. C. et al. APOE predicts amyloid-beta but not tau Alzheimer pathology in cognitively normal aging. Ann Neurol 67, 122-131 (2010).</p>
<p>ApoE4 markedly exacerbates tau-mediated neurodegeneration in a mouse model of tauopathy. Y Shi, Nature. 549Shi, Y. et al. ApoE4 markedly exacerbates tau-mediated neurodegeneration in a mouse model of tauopathy. Nature 549, 523-527 (2017).</p>
<p>APOE effects on regional tau in preclinical Alzheimer's disease. C B Young, Mol Neurodegener. 18Young, C. B. et al. APOE effects on regional tau in preclinical Alzheimer's disease. Mol Neurodegener 18, (2023).</p>
<p>Association of CD2AP neuronal deposits with Braak neurofibrillary stage in Alzheimer's disease. J Camacho, Brain Pathology. 32Camacho, J. et al. Association of CD2AP neuronal deposits with Braak neurofibrillary stage in Alzheimer's disease. Brain Pathology 32, (2022).</p>
<p>Associations of Alzheimer's disease risk variants with gene expression, amyloidosis, tauopathy, and neurodegeneration. M S Tan, Alzheimers Res Ther. 13Tan, M. S. et al. Associations of Alzheimer's disease risk variants with gene expression, amyloidosis, tauopathy, and neurodegeneration. Alzheimers Res Ther 13, (2021).</p>
<p>Quantitative genetics validates previous genetic variants and identifies novel genetic players influencing Alzheimer's disease cerebrospinal fluid biomarkers. M Ramos De Matos, Journal of Alzheimer's Disease. 66Ramos De Matos, M. et al. Quantitative genetics validates previous genetic variants and identifies novel genetic players influencing Alzheimer's disease cerebrospinal fluid biomarkers. Journal of Alzheimer's Disease 66, 639-652 (2018).</p>
<p>The metalloprotease ADAMTS4 generates N-truncated Aβ4-x species and marks oligodendrocytes as a source of amyloidogenic peptides in Alzheimer's disease. S Walter, Acta Neuropathol. 137Walter, S. et al. The metalloprotease ADAMTS4 generates N-truncated Aβ4-x species and marks oligodendrocytes as a source of amyloidogenic peptides in Alzheimer's disease. Acta Neuropathol 137, 239-257 (2019).</p>
<p>Pathophysiological function of ADAMTS enzymes on molecular mechanism of Alzheimer's disease. M S Gurses, M N Ural, M A Gulec, O Akyol, S Akyol, 10.14336/AD.2016.0111Aging and Disease. 7Gurses, M. S., Ural, M. N., Gulec, M. A., Akyol, O. &amp; Akyol, S. Pathophysiological function of ADAMTS enzymes on molecular mechanism of Alzheimer's disease. Aging and Disease vol. 7 479-490 Preprint at https://doi.org/10.14336/AD.2016.0111 (2016).</p>
<p>The Role of Reelin Signaling in Alzheimer's Disease. N N Yu, M S Tan, J T Yu, A M Xie, L Tan, 10.1007/s12035-015-9459-9Molecular Neurobiology. 53Yu, N. N., Tan, M. S., Yu, J. T., Xie, A. M. &amp; Tan, L. The Role of Reelin Signaling in Alzheimer's Disease. Molecular Neurobiology vol. 53 5692-5700 Preprint at https://doi.org/10.1007/s12035-015-9459-9 (2016).</p>
<p>A disintegrin and metalloproteinase with thrombospondin motifs 4 (ADAMTS-4) cleaves Reelin in an isoform-dependent manner. A Hisanaga, FEBS Lett. 586Hisanaga, A. et al. A disintegrin and metalloproteinase with thrombospondin motifs 4 (ADAMTS-4) cleaves Reelin in an isoform-dependent manner. FEBS Lett 586, 3349-3353 (2012).</p>
<p>Agrin Differentially Regulates the Rates of Axonal and Dendritic Elongation in Cultured Hippocampal Neurons. K B Mantych, A Ferreira, Journal of Neuroscience. 17Mantych, K. B. &amp; Ferreira, A. Agrin Differentially Regulates the Rates of Axonal and Dendritic Elongation in Cultured Hippocampal Neurons. Journal of Neuroscience 17, 6802-6809 (2001).</p>
<p>Rare coding variants in the phospholipase D3 gene confer risk for Alzheimer's disease. C Cruchaga, Nature. 505Cruchaga, C. et al. Rare coding variants in the phospholipase D3 gene confer risk for Alzheimer's disease. Nature 505, 550-554 (2014).</p>
<p>PLD3 affects axonal spheroids and network defects in Alzheimer's disease. P Yuan, Nature. 612Yuan, P. et al. PLD3 affects axonal spheroids and network defects in Alzheimer's disease. Nature 612, 328-337 (2022).</p>
<p>Spreading of pathology in neurodegenerative diseases: A focus on human studies. J Brettschneider, K Del Tredici, V M Y Lee, J Q Trojanowski, 10.1038/nrn3887Nature Reviews Neuroscience. 16109Brettschneider, J., Del Tredici, K., Lee, V. M. Y. &amp; Trojanowski, J. Q. Spreading of pathology in neurodegenerative diseases: A focus on human studies. Nature Reviews Neuroscience vol. 16 109-120 Preprint at https://doi.org/10.1038/nrn3887 (2015).</p>
<p>Protein transmission in neurodegenerative disease. C Peng, J Q Trojanowski, V M Lee, 10.1038/s41582-020-0333-7Nature Reviews Neurology. 16Peng, C., Trojanowski, J. Q. &amp; Lee, V. M. Y. Protein transmission in neurodegenerative disease. Nature Reviews Neurology vol. 16 199-212 Preprint at https://doi.org/10.1038/s41582-020-0333-7 (2020).</p>
<p>Direct downregulation of CNTNAP2 by STOX1A is associated with Alzheimer's disease. D Van Abel, Journal of Alzheimer's Disease. 31Van Abel, D. et al. Direct downregulation of CNTNAP2 by STOX1A is associated with Alzheimer's disease. Journal of Alzheimer's Disease 31, 793-800 (2012).</p>
<p>Tau Reduction Prevents Key Features of Autism in Mouse Models. C Tai, Neuron. 106e11Tai, C. et al. Tau Reduction Prevents Key Features of Autism in Mouse Models. Neuron 106, 421-437.e11 (2020).</p>
<p>What does CNTNAP2 reveal about autism spectrum disorder?. O Peñagarikano, D H Geschwind, 10.1016/j.molmed.2012.01.003Trends in Molecular Medicine. 18Peñagarikano, O. &amp; Geschwind, D. H. What does CNTNAP2 reveal about autism spectrum disorder? Trends in Molecular Medicine vol. 18 156-163 Preprint at https://doi.org/10.1016/j.molmed.2012.01.003 (2012).</p>
<p>Age-dependent formation of TMEM106B amyloid filaments in human brains. M Schweighauser, Nature. 605Schweighauser, M. et al. Age-dependent formation of TMEM106B amyloid filaments in human brains. Nature 605, 310-314 (2022).</p>
<p>Amyloid fibrils in FTLD-TDP are composed of TMEM106B and not TDP-43. Y X Jiang, Nature. 605Jiang, Y. X. et al. Amyloid fibrils in FTLD-TDP are composed of TMEM106B and not TDP-43. Nature 605, 304-309 (2022).</p>
<p>Homotypic fibrillization of TMEM106B across diverse neurodegenerative diseases. A Chang, Cell. 185Chang, A. et al. Homotypic fibrillization of TMEM106B across diverse neurodegenerative diseases. Cell 185, 1346-1355.e15 (2022).</p>
<p>INPP5D expression is associated with risk for Alzheimer's disease and induced by plaque-associated microglia. A P Tsai, Neurobiol Dis. 153Tsai, A. P. et al. INPP5D expression is associated with risk for Alzheimer's disease and induced by plaque-associated microglia. Neurobiol Dis 153, (2021).</p>
<p>INPP5D inhibition attenuates amyloid pathology through the regulation of microglial functions. P B Lin, Alzheimer's &amp; Dementia. 18Lin, P. B. et al. INPP5D inhibition attenuates amyloid pathology through the regulation of microglial functions. Alzheimer's &amp; Dementia 18, (2022).</p>
<p>Sex Differences in the Association of Global Amyloid and Regional Tau Deposition Measured by Positron Emission Tomography in Clinically Normal Older Adults. R F Buckley, JAMA Neurol. 76Buckley, R. F. et al. Sex Differences in the Association of Global Amyloid and Regional Tau Deposition Measured by Positron Emission Tomography in Clinically Normal Older Adults. JAMA Neurol 76, 542- 551 (2019).</p>
<p>Menopause Status Moderates Sex Differences in Tau Burden: A Framingham PET Study. R F Buckley, Ann Neurol. 92Buckley, R. F. et al. Menopause Status Moderates Sex Differences in Tau Burden: A Framingham PET Study. Ann Neurol 92, 11-22 (2022).</p>
<p>Sex Mediates Relationships Between Regional Tau Pathology and Cognitive Decline. R F Buckley, Ann Neurol. 88Buckley, R. F. et al. Sex Mediates Relationships Between Regional Tau Pathology and Cognitive Decline. Ann Neurol 88, 921-932 (2020).</p>
<p>Sex differences in Alzheimer's disease: metabolic reprogramming and therapeutic intervention. L A Demetrius, A Eckert, A Grimm, 10.1016/j.tem.2021.09.004Trends in Endocrinology and Metabolism. 32Demetrius, L. A., Eckert, A. &amp; Grimm, A. Sex differences in Alzheimer's disease: metabolic reprogramming and therapeutic intervention. Trends in Endocrinology and Metabolism vol. 32 963-979 Preprint at https://doi.org/10.1016/j.tem.2021.09.004 (2021).</p>
<p>The accumulation rate of tau aggregates is higher in females and younger amyloidpositive subjects. R Smith, Brain. 143Smith, R. et al. The accumulation rate of tau aggregates is higher in females and younger amyloid- positive subjects. Brain 143, 3805-3815 (2020).</p>
<p>Sex differences in the genetic predictors of Alzheimer's pathology. L Dumitrescu, Brain. 142Dumitrescu, L. et al. Sex differences in the genetic predictors of Alzheimer's pathology. Brain 142, 2581- 2589 (2019).</p>
<p>Sex differences in Alzheimer risk Brain imaging of endocrine vs chronologic aging. L Mosconi, Mosconi, L. et al. Sex differences in Alzheimer risk Brain imaging of endocrine vs chronologic aging. (2017).</p>
<p>Sex differences in hippocampal β-amyloid accumulation in the triple-transgenic mouse model of Alzheimer's disease and the potential role of local estrogens. Y.-T Hu, Front Neurosci. 17Hu, Y.-T. et al. Sex differences in hippocampal β-amyloid accumulation in the triple-transgenic mouse model of Alzheimer's disease and the potential role of local estrogens. Front Neurosci 17, (2023).</p>
<p>Sex differences in β-amyloid accumulation in 3xTg-AD mice: Role of neonatal sex steroid hormone exposure. J C Carroll, Brain Res. 1366Carroll, J. C. et al. Sex differences in β-amyloid accumulation in 3xTg-AD mice: Role of neonatal sex steroid hormone exposure. Brain Res 1366, 233-245 (2010).</p>
<p>Sex-related differences in tau Positron Emission Tomography (PET) and the effects of Hormone Therapy (HT). J K Wisch, Alzheimer Dis Assoc Disord. 35Wisch, J. K. et al. Sex-related differences in tau Positron Emission Tomography (PET) and the effects of Hormone Therapy (HT). Alzheimer Dis Assoc Disord 35, 164-168 (2021).</p>
<p>Perimenopause as a neurological transition state. R D Brinton, J Yao, F Yin, W J Mack, E Cadenas, 10.1038/nrendo.2015.82Nature Reviews Endocrinology. 11Brinton, R. D., Yao, J., Yin, F., Mack, W. J. &amp; Cadenas, E. Perimenopause as a neurological transition state. Nature Reviews Endocrinology vol. 11 393-405 Preprint at https://doi.org/10.1038/nrendo.2015.82 (2015).</p>
<p>Sex differences in immune responses. S L Klein, K L Flanagan, 10.1038/nri.2016.90Nature Reviews Immunology. 16Klein, S. L. &amp; Flanagan, K. L. Sex differences in immune responses. Nature Reviews Immunology vol. 16 626-638 Preprint at https://doi.org/10.1038/nri.2016.90 (2016).</p>
<p>Alzheimer's disease-related transcriptional sex differences in myeloid cells. I Coales, J Neuroinflammation. 19Coales, I. et al. Alzheimer's disease-related transcriptional sex differences in myeloid cells. J Neuroinflammation 19, (2022).</p>
<p>The Brain's Default Mode Network. M E Raichle, Annu Rev Neurosci. 38Raichle, M. E. The Brain's Default Mode Network. Annu Rev Neurosci 38, 433-447 (2015).</p>
<p>Selective impairment of hippocampus and posterior hub areas in Alzheimer's disease: An MEG-based multiplex network study. M Yu, Brain. 140Yu, M. et al. Selective impairment of hippocampus and posterior hub areas in Alzheimer's disease: An MEG-based multiplex network study. Brain 140, 1466-1485 (2017).</p>
<p>Cortical Hubs Revealed by Intrinsic Functional Connectivity: Mapping, Assessment of Stability, and Relation to Alzheimer's Disease. R L Buckner, Journal of Neuroscience. 29Buckner, R. L. et al. Cortical Hubs Revealed by Intrinsic Functional Connectivity: Mapping, Assessment of Stability, and Relation to Alzheimer's Disease. Journal of Neuroscience 29, 1860-1873 (2009).</p>
<p>The brain's default network: Anatomy, function, and relevance to disease. R L Buckner, J R Andrews-Hanna, D L Schacter, Ann N Y Acad Sci. 1124Buckner, R. L., Andrews-Hanna, J. R. &amp; Schacter, D. L. The brain's default network: Anatomy, function, and relevance to disease. Ann N Y Acad Sci 1124, 1-38 (2008).</p>
<p>Four distinct trajectories of tau deposition identified in Alzheimer's disease. J W Vogel, Nat Med. 27Vogel, J. W. et al. Four distinct trajectories of tau deposition identified in Alzheimer's disease. Nat Med 27, 871-881 (2021).</p>
<p>Genetic variants in Alzheimer disease-molecular and brain network approaches. C Gaiteri, S Mostafavi, C J Honey, P L De Jager, D A Bennett, Nat Rev Neurol. 12Gaiteri, C., Mostafavi, S., Honey, C. J., De Jager, P. L. &amp; Bennett, D. A. Genetic variants in Alzheimer disease-molecular and brain network approaches. Nat Rev Neurol 12, 413-427 (2016).</p>
<p>Imaging Transcriptomics in Neurodegenerative Diseases. M Mroczek, A Desouky, W Sirry, Journal of Neuroimaging. 31Mroczek, M., Desouky, A. &amp; Sirry, W. Imaging Transcriptomics in Neurodegenerative Diseases. Journal of Neuroimaging 31, 244-250 (2021).</p>
<p>. W.-T Chen, Spatial Transcriptomics and In Situ Sequencing to Study Alzheimer's Disease. Cell. 0Chen, W.-T. et al. Spatial Transcriptomics and In Situ Sequencing to Study Alzheimer's Disease. Cell 0, 1- 16 (2020).</p>
<p>. I Castanho, 10.1016/j.celrep.2020.01.063Transcriptional Signatures of Tau and Amyloid Neuropathology. Cell Rep. Castanho, I. et al. Transcriptional Signatures of Tau and Amyloid Neuropathology. Cell Rep 2040-2054 (2020) doi:10.1016/j.celrep.2020.01.063.</p>
<p>Single-cell transcriptomic analysis of Alzheimer's disease. H Mathys, Nature. 570Mathys, H. et al. Single-cell transcriptomic analysis of Alzheimer's disease. Nature 570, 332-337 (2019).</p>
<p>Gene expression links functional networks across cortex and striatum. K M Anderson, Nat Commun. 91428Anderson, K. M. et al. Gene expression links functional networks across cortex and striatum. Nat Commun 9, 1428 (2018).</p>
<p>Morphometric Similarity Networks Detect Microscale Cortical Organization and Predict Inter-Individual Cognitive Variation. J Seidlitz, 10.1016/j.neuron.2017.11.039Neuron. 231247Seidlitz, J. et al. Morphometric Similarity Networks Detect Microscale Cortical Organization and Predict Inter-Individual Cognitive Variation. Neuron 231-247 (2018) doi:10.1016/j.neuron.2017.11.039.</p>
<p>Adolescence is associated with genomically patterned consolidation of the hubs of the human brain connectome. K J Whitaker, Proceedings of the National Academy of Sciences. 113Whitaker, K. J. et al. Adolescence is associated with genomically patterned consolidation of the hubs of the human brain connectome. Proceedings of the National Academy of Sciences 113, 9105-9110 (2016).</p>
<p>Correlated gene expression supports synchronous activity in brain networks. J Richiardi, Science. 348Richiardi, J. et al. Correlated gene expression supports synchronous activity in brain networks. Science (1979) 348, 1241-1244 (2015).</p>
<p>Mapping gene transcription and neurocognition across human neocortex. J Y Hansen, 10.1038/s41562-021-01082-zNat Hum Behav. Hansen, J. Y. et al. Mapping gene transcription and neurocognition across human neocortex. Nat Hum Behav (2021) doi:10.1038/s41562-021-01082-z.</p>
<p>Conservative and disruptive modes of adolescent change in brain functional connectivity. F Váša, 10.1101/604843Proc Natl Acad Sci U S A. 604843Váša, F. et al. Conservative and disruptive modes of adolescent change in brain functional connectivity. Proc Natl Acad Sci U S A 604843 (2019) doi:10.1101/604843.</p>
<p>Transcriptional profiles of supragranular-enriched genes associate with corticocortical network architecture in the human brain. F M Krienen, B T T Yeo, T Ge, R L Buckner, C C Sherwood, Proceedings of the National Academy of Sciences. 113Krienen, F. M., Yeo, B. T. T., Ge, T., Buckner, R. L. &amp; Sherwood, C. C. Transcriptional profiles of supragranular-enriched genes associate with corticocortical network architecture in the human brain. Proceedings of the National Academy of Sciences 113, E469-E478 (2016).</p>
<p>Shaping brain structure: Genetic and phylogenetic axes of macroscale organization of cortical thickness. S L Valk, Sci. Adv. 6Valk, S. L. et al. Shaping brain structure: Genetic and phylogenetic axes of macroscale organization of cortical thickness. Sci. Adv 6, (2020).</p>
<p>Genetic influences on hub connectivity of the human connectome. A Arnatkeviciute, Nat Commun. 12Arnatkeviciute, A. et al. Genetic influences on hub connectivity of the human connectome. Nat Commun 12, (2021).</p>
<p>Convergent molecular, cellular, and cortical neuroimaging signatures of major depressive disorder. K M Anderson, Proceedings of the National Academy of Sciences. 117Anderson, K. M. et al. Convergent molecular, cellular, and cortical neuroimaging signatures of major depressive disorder. Proceedings of the National Academy of Sciences 117, 25138-25149 (2020).</p>
<p>Neurogenetic profiles delineate large-scale connectivity dynamics of the human brain. I Diez, J Sepulcre, Nat Commun. 9Diez, I. &amp; Sepulcre, J. Neurogenetic profiles delineate large-scale connectivity dynamics of the human brain. Nat Commun 9, 1-10 (2018).</p>
<p>Dynamical consequences of regional heterogeneity in the brain's transcriptional landscape. G Deco, Sci. Adv. 7Deco, G. et al. Dynamical consequences of regional heterogeneity in the brain's transcriptional landscape. Sci. Adv vol. 7 https://www.science.org (2021).</p>
<p>Hierarchy of transcriptomic specialization across human cortex captured by structural neuroimaging topography. J B Burt, Nat Neurosci. 21Burt, J. B. et al. Hierarchy of transcriptomic specialization across human cortex captured by structural neuroimaging topography. Nat Neurosci 21, 1251-1259 (2018).</p>
<p>Gene expression links functional networks across cortex and striatum. K M Anderson, Nat Commun. 9Anderson, K. M. et al. Gene expression links functional networks across cortex and striatum. Nat Commun 9, (2018).</p>
<p>Genetic influences on hub connectivity of the human connectome. A Arnatkeviciute, Nat Commun. 12Arnatkeviciute, A. et al. Genetic influences on hub connectivity of the human connectome. Nat Commun 12, (2021).</p>
<p>Imaging transcriptomics: Convergent cellular, transcriptomic, and molecular neuroimaging signatures in the healthy adult human brain. D Martins, Cell Rep. 37Martins, D. et al. Imaging transcriptomics: Convergent cellular, transcriptomic, and molecular neuroimaging signatures in the healthy adult human brain. Cell Rep 37, (2021).</p>
<p>Integrative structural, functional, and transcriptomic analyses of sex-biased brain organization in humans. S Liu, J Seidlitz, Jonathan ; Blumenthal, L Clasen, A Raznahan, Proc Natl Acad Sci U S A. 117Liu, S., Seidlitz, J., Blumenthal, jonathan;, Clasen, L. &amp; Raznahan, A. Integrative structural, functional, and transcriptomic analyses of sex-biased brain organization in humans. Proc Natl Acad Sci U S A 117, 18788-18798 (2020).</p>
<p>Network structure and transcriptomic vulnerability shape atrophy in frontotemporal dementia. G Shafiei, Brain. 146Shafiei, G. et al. Network structure and transcriptomic vulnerability shape atrophy in frontotemporal dementia. Brain 146, 321-336 (2023).</p>
<p>Regional transcriptional architecture of Parkinson's disease pathogenesis and network spread. B Freeze, S Pandya, Y Zeighami, A Raj, Brain. 142Freeze, B., Pandya, S., Zeighami, Y. &amp; Raj, A. Regional transcriptional architecture of Parkinson's disease pathogenesis and network spread. Brain 142, 3072-3085 (2019).</p>
<p>Local vulnerability and global connectivity jointly shape neurodegenerative disease propagation. Y Zheng, 10.1371/journal.pbio.3000495PLoS Biol. 127Zheng, Y. et al. Local vulnerability and global connectivity jointly shape neurodegenerative disease propagation. PLoS Biol 1-27 (2019) doi:10.1371/journal.pbio.3000495.</p>
<p>Brain atrophy in idiopathic REM sleep behaviour disorder is a sign of incipient synucleinopathy. D Arnaldi, P Mattioli, 10.1093/brain/awac242Brain : a journal of neurology. 145Arnaldi, D. &amp; Mattioli, P. Brain atrophy in idiopathic REM sleep behaviour disorder is a sign of incipient synucleinopathy. Brain : a journal of neurology vol. 145 2949-2951 Preprint at https://doi.org/10.1093/brain/awac242 (2022).</p>
<p>Differences in network controllability and regional gene expression underlie hallucinations in Parkinson's disease. A Zarkali, Brain. 143Zarkali, A. et al. Differences in network controllability and regional gene expression underlie hallucinations in Parkinson's disease. Brain 143, 3435-3448 (2021).</p>
<p>Differentially targeted seeding reveals unique pathological alpha-synuclein propagation patterns. S Rahayel, Brain. 145Rahayel, S. et al. Differentially targeted seeding reveals unique pathological alpha-synuclein propagation patterns. Brain 145, 1743-1756 (2022).</p>
<p>Cortical patterning of abnormal morphometric similarity in psychosis is associated with brain expression of schizophrenia-related genes. S E Morgan, Proc Natl Acad Sci U S A. 116Morgan, S. E. et al. Cortical patterning of abnormal morphometric similarity in psychosis is associated with brain expression of schizophrenia-related genes. Proc Natl Acad Sci U S A 116, 9604-9609 (2019).</p>
<p>Connectome Disconnectivity and Cortical Gene Expression in Patients With Schizophrenia. I A C Romme, M A De Reus, R A Ophoff, R S Kahn, Van Den, M P Heuvel, Biol Psychiatry. 81Romme, I. A. C., de Reus, M. A., Ophoff, R. A., Kahn, R. S. &amp; van den Heuvel, M. P. Connectome Disconnectivity and Cortical Gene Expression in Patients With Schizophrenia. Biol Psychiatry 81, 495- 502 (2017).</p>
<p>Schizotypy-Related Magnetization of Cortex in Healthy Adolescence Is Colocated With Expression of Schizophrenia-Related Genes. R Romero-Garcia, Biol Psychiatry. 88Romero-Garcia, R. et al. Schizotypy-Related Magnetization of Cortex in Healthy Adolescence Is Colocated With Expression of Schizophrenia-Related Genes. Biol Psychiatry 88, 248-259 (2020).</p>
<p>Cell type-specific manifestations of cortical thickness heterogeneity in schizophrenia. Di Biase, M A , Mol Psychiatry. 27Di Biase, M. A. et al. Cell type-specific manifestations of cortical thickness heterogeneity in schizophrenia. Mol Psychiatry 27, 2052-2060 (2022).</p>
<p>Brain circuit-gene expression relationships and neuroplasticity of multisensory cortices in blind children. L Ortiz-Terán, Proc Natl Acad Sci U S A. 114Ortiz-Terán, L. et al. Brain circuit-gene expression relationships and neuroplasticity of multisensory cortices in blind children. Proc Natl Acad Sci U S A 114, 6830-6835 (2017).</p>
<p>Early-life trauma endophenotypes and brain circuit-gene expression relationships in functional neurological (conversion) disorder. I Diez, Mol Psychiatry. 26Diez, I. et al. Early-life trauma endophenotypes and brain circuit-gene expression relationships in functional neurological (conversion) disorder. Mol Psychiatry 26, 3817-3828 (2021).</p>
<p>Regional gene expression signatures are associated with sex-specific functional connectivity changes in depression. A Talishinsky, Nat Commun. 13Talishinsky, A. et al. Regional gene expression signatures are associated with sex-specific functional connectivity changes in depression. Nat Commun 13, (2022).</p>
<p>Connectome gradient dysfunction in major depression and its association with gene expression profiles and treatment outcomes. M Xia, Mol Psychiatry. 27Xia, M. et al. Connectome gradient dysfunction in major depression and its association with gene expression profiles and treatment outcomes. Mol Psychiatry 27, 1384-1393 (2022).</p>
<p>Synaptic and transcriptionally downregulated genes are associated with cortical thickness differences in autism. R Romero-Garcia, V Warrier, E T Bullmore, S Baron-Cohen, R A Bethlehem, Mol Psychiatry. 24Romero-Garcia, R., Warrier, V., Bullmore, E. T., Baron-Cohen, S. &amp; Bethlehem, R. A. I. Synaptic and transcriptionally downregulated genes are associated with cortical thickness differences in autism. Mol Psychiatry 24, 1053-1064 (2019).</p>
<p>Structural tract alterations predict downstream tau accumulation in amyloidpositive older individuals. H I L Jacobs, Nat Neurosci. 21Jacobs, H. I. L. et al. Structural tract alterations predict downstream tau accumulation in amyloid- positive older individuals. Nat Neurosci 21, 424-431 (2018).</p>
<p>Regional Aβ-tau interactions promote onset and acceleration of Alzheimer's disease tau spreading. W J Lee, Neuron. 110Lee, W. J. et al. Regional Aβ-tau interactions promote onset and acceleration of Alzheimer's disease tau spreading. Neuron 110, 1932-1943.e5 (2022).</p>
<p>Amyloid-β plaques enhance Alzheimer's brain tau-seeded pathologies by facilitating neuritic plaque tau aggregation. Z He, Nat Med. 24He, Z. et al. Amyloid-β plaques enhance Alzheimer's brain tau-seeded pathologies by facilitating neuritic plaque tau aggregation. Nat Med 24, 29-38 (2018).</p>
<p>Amyloid-Beta (Aβ) Plaques Promote Seeding and Spreading of Alpha-Synuclein and Tau in a Mouse Model of Lewy Body Disorders with Aβ Pathology. F Bassil, Neuron. 105Bassil, F. et al. Amyloid-Beta (Aβ) Plaques Promote Seeding and Spreading of Alpha-Synuclein and Tau in a Mouse Model of Lewy Body Disorders with Aβ Pathology. Neuron 105, 260-275.e6 (2020).</p>
<p>A critical appraisal of the pathogenic protein spread hypothesis of neurodegeneration. D M Walsh, D J Selkoe, Nat Rev Neurosci. 17Walsh, D. M. &amp; Selkoe, D. J. A critical appraisal of the pathogenic protein spread hypothesis of neurodegeneration. Nat Rev Neurosci 17, 251-260 (2016).</p>
<p>Ageing and neuronal vulnerability. M P Mattson, T Magnus, Nat Rev Neurosci. 7Mattson, M. P. &amp; Magnus, T. Ageing and neuronal vulnerability. Nat Rev Neurosci 7, 278-294 (2006).</p>
<p>The Alzheimer's Disease Neuroimaging Initiative 3: Continued innovation for clinical trial improvement. M W Weiner, 13Alzheimer's and DementiaWeiner, M. W. et al. The Alzheimer's Disease Neuroimaging Initiative 3: Continued innovation for clinical trial improvement. Alzheimer's and Dementia 13, 561-571 (2017).</p>
<p>Update of the Alzheimer's Disease Neuroimaging Initiative: A review of papers published since its inception. M W Weiner, 11Alzheimer's and DementiaWeiner, M. W. et al. 2014 Update of the Alzheimer's Disease Neuroimaging Initiative: A review of papers published since its inception. Alzheimer's and Dementia 11, e1-e120 (2015).</p>
<p>Older adults with cognitive complaints show brain atrophy similar to that of amnestic MCI. A J Saykin, Neurology. 67Saykin, A. J. et al. Older adults with cognitive complaints show brain atrophy similar to that of amnestic MCI. Neurology 67, 834-842 (2006).</p>
<p>Association between anticholinergic medication use and cognition, brain metabolism, and brain atrophy in cognitively normal older adults. S L Risacher, JAMA Neurol. 73Risacher, S. L. et al. Association between anticholinergic medication use and cognition, brain metabolism, and brain atrophy in cognitively normal older adults. JAMA Neurol 73, 721-732 (2016).</p>
<p>Tau-Related White-Matter Alterations Along Spatially Selective Pathways. Q Wen, Neuroimage. 226117560Wen, Q. et al. Tau-Related White-Matter Alterations Along Spatially Selective Pathways. Neuroimage 226, 117560 (2020).</p>
<p>Alzheimer disease brain atrophy subtypes are associated with cognition and rate of decline. S L Risacher, Neurology. 89Risacher, S. L. et al. Alzheimer disease brain atrophy subtypes are associated with cognition and rate of decline. Neurology 89, 2176-2186 (2017).</p>
<p>Visual contrast sensitivity is associated with the presence of cerebral amyloid and tau deposition. S L Risacher, Brain Commun. 2Risacher, S. L. et al. Visual contrast sensitivity is associated with the presence of cerebral amyloid and tau deposition. Brain Commun 2, 1-14 (2020).</p>
<p>Comparing positron emission tomography imaging and cerebrospinal fluid measurements of β-amyloid. S M Landau, Ann Neurol. 74Landau, S. M. et al. Comparing positron emission tomography imaging and cerebrospinal fluid measurements of β-amyloid. Ann Neurol 74, 826-836 (2013).</p>
<p>Detecting earlier stages of amyloid deposition using PET in cognitively normal elderly adults. T Guo, S M Landau, W J Jagust, Neurology. 94Guo, T., Landau, S. M. &amp; Jagust, W. J. Detecting earlier stages of amyloid deposition using PET in cognitively normal elderly adults. Neurology 94, E1512-E1524 (2020).</p>
<p>Considerations and code for partial volume correcting [18F]-AV-1451 tau PET data. S L Baker, A Maass, W J Jagust, Data Brief. 15Baker, S. L., Maass, A. &amp; Jagust, W. J. Considerations and code for partial volume correcting [18F]-AV- 1451 tau PET data. Data Brief 15, 648-657 (2017).</p>
<p>Comparison of multiple tau-PET measures as biomarkers in aging and Alzheimer's disease. A Maass, Neuroimage. 157Maass, A. et al. Comparison of multiple tau-PET measures as biomarkers in aging and Alzheimer's disease. Neuroimage 157, 448-463 (2017).</p>
<p>Comparison of multiple tau-PET measures as biomarkers in aging and Alzheimer's disease. A Maass, Neuroimage. 157Maass, A. et al. Comparison of multiple tau-PET measures as biomarkers in aging and Alzheimer's disease. Neuroimage 157, 448-463 (2017).</p>
<p>PET Imaging of Tau Deposition in the Aging Human Brain. M Schöll, Neuron. 89Schöll, M. et al. PET Imaging of Tau Deposition in the Aging Human Brain. Neuron 89, 971-982 (2016).</p>
<p>Visual contrast sensitivity is associated with the presence of cerebral amyloid and tau deposition. S L Risacher, Brain Commun. 2Risacher, S. L. et al. Visual contrast sensitivity is associated with the presence of cerebral amyloid and tau deposition. Brain Commun 2, 1-14 (2020).</p>
<p>Plasma amyloid beta levels are associated with cerebral amyloid and tau deposition. S L Risacher, Assessment and Disease Monitoring. 11Alzheimer's and Dementia: DiagnosisRisacher, S. L. et al. Plasma amyloid beta levels are associated with cerebral amyloid and tau deposition. Alzheimer's and Dementia: Diagnosis, Assessment and Disease Monitoring 11, 510-519 (2019).</p>
<p>An automated labeling system for subdividing the human cerebral cortex on MRI scans into gyral based regions of interest. R S Desikan, Neuroimage. 31Desikan, R. S. et al. An automated labeling system for subdividing the human cerebral cortex on MRI scans into gyral based regions of interest. Neuroimage 31, 968-980 (2006).</p>
<p>A practical guide to linking brain-wide gene expression and neuroimaging data. A Arnatkevicȋūtė, B D Fulcher, A Fornito, Neuroimage. 189Arnatkevicȋūtė, A., Fulcher, B. D. &amp; Fornito, A. A practical guide to linking brain-wide gene expression and neuroimaging data. Neuroimage 189, 353-367 (2019).</p>
<p>Comparing spatial null models for brain maps. R D Markello, B Misic, Neuroimage. 236118052Markello, R. D. &amp; Misic, B. Comparing spatial null models for brain maps. Neuroimage 236, 118052 (2021).</p>
<p>Adolescent tuning of association cortex in human structural brain networks. F Váša, Cerebral Cortex. 28Váša, F. et al. Adolescent tuning of association cortex in human structural brain networks. Cerebral Cortex 28, 281-294 (2018).</p>
<p>On testing for spatial correspondence between maps of human brain structure and function. A F Alexander-Bloch, Neuroimage. 178Alexander-Bloch, A. F. et al. On testing for spatial correspondence between maps of human brain structure and function. Neuroimage 178, 540-551 (2018).</p>
<p>Statistical testing in transcriptomic-neuroimaging studies: A how-to and evaluation of methods assessing spatial and gene specificity. Y Wei, Hum Brain Mapp. 43Wei, Y. et al. Statistical testing in transcriptomic-neuroimaging studies: A how-to and evaluation of methods assessing spatial and gene specificity. Hum Brain Mapp 43, 885-901 (2022).</p>
<p>Tau-mediated neurodegeneration in Alzheimer's disease and related disorders. C Ballatore, V M Y Lee, J Q Trojanowski, 10.1038/nrn2194Nature Reviews Neuroscience. 8Ballatore, C., Lee, V. M. Y. &amp; Trojanowski, J. Q. Tau-mediated neurodegeneration in Alzheimer's disease and related disorders. Nature Reviews Neuroscience vol. 8 663-672 Preprint at https://doi.org/10.1038/nrn2194 (2007).</p>
<p>. V M Lee, .-Y Goedert, M Trojanowski, J Q Neurodegenerative Tauopathies, Lee, V. M.-Y., Goedert, M. &amp; Trojanowski, J. Q. NEURODEGENERATIVE TAUOPATHIES. www.annualreviews.org (2001).</p>
<p>Advances in tau-focused drug discovery for Alzheimer's disease and related tauopathies. K R Brunden, J Q Trojanowski, V M Lee, 10.1038/nrd2959Nature Reviews Drug Discovery. 8Brunden, K. R., Trojanowski, J. Q. &amp; Lee, V. M. Y. Advances in tau-focused drug discovery for Alzheimer's disease and related tauopathies. Nature Reviews Drug Discovery vol. 8 783-793 Preprint at https://doi.org/10.1038/nrd2959 (2009).</p>
<p>A Brief Overview of Tauopathy: Causes, Consequences, and Therapeutic Strategies. M E Orr, A C Sullivan, B Frost, 10.1016/j.tips.2017.03.011Trends in Pharmacological Sciences. 38Orr, M. E., Sullivan, A. C. &amp; Frost, B. A Brief Overview of Tauopathy: Causes, Consequences, and Therapeutic Strategies. Trends in Pharmacological Sciences vol. 38 637-648 Preprint at https://doi.org/10.1016/j.tips.2017.03.011 (2017).</p>
<p>Selective functional, regional, and neuronal vulnerability in frontotemporal dementia. W W Seeley, Curr Opin Neurol. 21Seeley, W. W. Selective functional, regional, and neuronal vulnerability in frontotemporal dementia. Curr Opin Neurol 21, 701-707 (2008).</p>
<p>. D A Olszewska, R Lonergan, E M Fallon, T Lynch, 10.1007/s11910-016-0707-9Genetics of Frontotemporal Dementia. Current Neurology and Neuroscience Reports. 16Olszewska, D. A., Lonergan, R., Fallon, E. M. &amp; Lynch, T. Genetics of Frontotemporal Dementia. Current Neurology and Neuroscience Reports vol. 16 Preprint at https://doi.org/10.1007/s11910-016-0707-9 (2016).</p>
<p>. J Bang, S Spina, B L Miller, 10.1016/S0140-6736(15Frontotemporal dementia. The Lancet. 386Bang, J., Spina, S. &amp; Miller, B. L. Frontotemporal dementia. The Lancet vol. 386 1672-1682 Preprint at https://doi.org/10.1016/S0140-6736(15)00461-4 (2015).</p>
<p>Clinico-genetic findings in 509 frontotemporal dementia patients. M Wagner, 10.1038/s41380-021-01271-2Mol Psychiatry. Wagner, M. et al. Clinico-genetic findings in 509 frontotemporal dementia patients. Mol Psychiatry (2021) doi:10.1038/s41380-021-01271-2.</p>
<p>The heritability and genetics of frontotemporal lobar degeneration. J D Rohrer, Rohrer, J. D. et al. The heritability and genetics of frontotemporal lobar degeneration. (2009).</p>
<p>Frontotemporal dementias: A review. N D Weder, R Aziz, K Wilkins, R R Tampi, 10.1186/1744-859X-6-15Annals of General Psychiatry. 6Weder, N. D., Aziz, R., Wilkins, K. &amp; Tampi, R. R. Frontotemporal dementias: A review. Annals of General Psychiatry vol. 6 Preprint at https://doi.org/10.1186/1744-859X-6-15 (2007).</p>
<p>An update on genetic frontotemporal dementia. C V Greaves, J D Rohrer, 10.1007/s00415-019-09363-4Journal of Neurology. 266Greaves, C. V. &amp; Rohrer, J. D. An update on genetic frontotemporal dementia. Journal of Neurology vol. 266 2075-2086 Preprint at https://doi.org/10.1007/s00415-019-09363-4 (2019).</p>
<p>Advances and controversies in frontotemporal dementia: diagnosis, biomarkers, and therapeutic considerations. J D Rohrer, Lancet Neurol. 21Rohrer, J. D. et al. Advances and controversies in frontotemporal dementia: diagnosis, biomarkers, and therapeutic considerations. Lancet Neurol vol. 21 www.thelancet.com/neurology (2022).</p>
<p>A mesoscale connectome of the mouse brain. S W Oh, Nature. 508Oh, S. W. et al. A mesoscale connectome of the mouse brain. Nature 508, 207-214 (2014).</p>
<p>Complex network measures of brain connectivity: Uses and interpretations. M Rubinov, O Sporns, Neuroimage. 52Rubinov, M. &amp; Sporns, O. Complex network measures of brain connectivity: Uses and interpretations. Neuroimage 52, 1059-1069 (2010).</p>
<p>Weight-conserving characterization of complex functional brain networks. M Rubinov, O Sporns, Neuroimage. 56Rubinov, M. &amp; Sporns, O. Weight-conserving characterization of complex functional brain networks. Neuroimage 56, 2068-2079 (2011).</p>
<p>Genomic Expression Programs in the Response of Yeast Cells to Environmental Changes □ D. A P Gasch, Mol Biol Cell. 11Gasch, A. P. et al. Genomic Expression Programs in the Response of Yeast Cells to Environmental Changes □ D. Mol Biol Cell 11, 4241-4257 (2000).</p>
<p>Maximization of negative correlations in time-course gene expression data for enhancing understanding of molecular pathways. T Zeng, J Li, Nucleic Acids Res. 38Zeng, T. &amp; Li, J. Maximization of negative correlations in time-course gene expression data for enhancing understanding of molecular pathways. Nucleic Acids Res 38, (2009).</p>
<p>Correlated gene modules uncovered by high-precision single-cell transcriptomics. A R Chapman, Proc Natl Acad Sci U S A. 119Chapman, A. R. et al. Correlated gene modules uncovered by high-precision single-cell transcriptomics. Proc Natl Acad Sci U S A 119, (2022).</p>
<p>Gene set enrichment analysis: A knowledge-based approach for interpreting genome-wide expression profiles. A Subramanian, www.pnas.orgcgidoi10.1073pnas.0506580102Subramanian, A. et al. Gene set enrichment analysis: A knowledge-based approach for interpreting genome-wide expression profiles. www.pnas.orgcgidoi10.1073pnas.0506580102 (2005).</p>
<p>Overcoming false-positive gene-category enrichment in the analysis of spatially resolved transcriptomic brain atlas data. B D Fulcher, A Arnatkeviciute, A Fornito, Nat Commun. 122669Fulcher, B. D., Arnatkeviciute, A. &amp; Fornito, A. Overcoming false-positive gene-category enrichment in the analysis of spatially resolved transcriptomic brain atlas data. Nat Commun 12, 2669 (2021).</p>
<p>Acknowledgments: Funding: This work was supported by several U.S. National Institute of Aging (NIA) and Alzheimer's Association (AA) grants: M.Y. is supported by grants from the Alzheimer's Association (AARF-22-722571) and the National Institute on Aging (U19AG074879. M Ashburner, R01 AG019771, P30 AG072976, U01 AG072177, and U01 AG068057). Author contributions. M.Y., O.S., A.J.S.25Gene Ontology: tool for the unification of biology. S.R. Writing -review &amp; editing: All the authorsAshburner, M. et al. Gene Ontology: tool for the unification of biology. Nature 25, 25-29 (2000). Acknowledgments: Funding: This work was supported by several U.S. National Institute of Aging (NIA) and Alzheimer's Association (AA) grants: M.Y. is supported by grants from the Alzheimer's Association (AARF-22-722571) and the National Institute on Aging (U19AG074879, R01 AG019771, P30 AG072976, U01 AG072177, and U01 AG068057). Author contributions: Conceptualization: M.Y., O.S., A.J.S Methodology: M.Y., O.S., S.R. Investigation: M.Y., S.R. Visualization: M.Y. Funding acquisition: M.Y., A.J.S., K.N. Project administration: A.J.S., M.Y. Supervision: M.Y., A.J.S., O.S., S.R. Writing -original draft: M.Y., O.S., A.J.S., S.R. Writing -review &amp; editing: All the authors</p>            </div>
        </div>

    </div>
</body>
</html>